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Chapter 1
General introduction
1.1 Introduction
Mycobacterium tuberculosis accounts for nearly 2 million deaths per year and
is the predominant cause of death in HIV patients [Check, 2007]. At present,
tuberculosis is treated with a cocktail of antibiotics for at least six months. In
the first two months, daily dosages of the first-line drugs isoniazid, rifampin,
pyrazinamide, and ethambutol are applied, followed by four months treatment
with isoniazid and rifampin alone [Mitchison, 2005]. This very long treatment is
due to populations of M. tuberculosis in a metabolic resting state, referred to as
dormancy or latency. In this resting state the bacteria can reside within human
macrophages for many years, without causing active disease. Dormant my-
cobacteria display increased cell envelope thickness and significantly remodeled
metabolic routes as compared with the replicating state, e.g. nucleic acid syn-
thesis and protein synthesis are strongly down-regulated in this non-replicating
state [Wayne & Sohaskey, 2001]. Currently used antibiotics have poor activity
against non-replicating bacilli [Gomez & McKinney, 2004] due to low cell enve-
lope penetration and decreased importance of the metabolic pathways targeted
by most drugs.
Patients often experience difficulties following a long-term treatment regi-
men, resulting in low treatment compliance, which in turn directly contributes
to the emergence of multidrug- and extensively drug-resistant strains of M.
tuberculosis [Check, 2007,Dye, 2009]. Infections with these drug-resistant my-
cobacterial strains require an even longer chemotherapy of 6-24 months [Gandhi
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et al., 2010,Koul et al., 2011].
For improvement of current tuberculosis treatment development of novel
antimycobacterial compounds as well as the discovery, validation and charac-
terization of new target proteins are of key importance [Bald & Koul, 2010,Dye
& Williams, 2010,Koul et al., 2011,Russel et al., 2010].
1.1.1 Energy metabolism as target pathway for antibacte-
rials
The antibacterial pyrazinamide, in clinical use as first-line tuberculosis drug
since the early eighties [Mitchison, 1985], provided the first indication that en-
ergy metabolism could be an attractive target for drug development. Pyrazi-
namide is hydrolyzed within the mycobacterial cell, yielding the active entity,
pyrazinoic acid. Pyrazinoic acid is thought to act as a weak acid, interfering
with the bacterial proton motive force [Zhang et al., 2003].
In 2005, two enzymes complexes of respiratory ATP synthesis were reported
as new targets of antituberculosis drugs: NADH dehydrogenase [Weinstein et al.,
2005] and ATP synthase [Andries et al., 2005]. The phenothiazines and phenoth-
iazine analogues inhibit the type II NADH dehydrogenase in M. tuberculosis.
Phenothiazine inhibition of NADH oxidation strongly suppresses oxygen con-
sumption and ATP synthesis activity by M. tuberculosis membranes [Boshoff et
al., 2004,Weinstein et al., 2005,Yano et al., 2006]. Moreover, preventing NADH
oxidation can increase the NADH/NAD+ ratio, leading to disturbed cellular
redox balance [Rao et al., 2008].
Diarylquinolines inhibit ATP synthesis and are active on drug-sensitive and
drug-resistant M. tuberculosis strains [Andries et al., 2005,Diacon et al., 2009,
Huitric et al., 2007,Koul et al., 2007]. Diarylquinoline lead compound TMC207
is bactericidal against replicating and non-replicating mycobacteria [Koul et al.,
2007,Koul et al., 2008,Rao et al., 2008]. Interestingly, TMC207 shows a delayed
bactericidal action, with little effect in the first days of drug addition and onset
of bacterial killing after 3-4 days [Lounis et al., 2008, Rustomjee et al., 2008].
Mycobacterium leprae and Mycobacterium ulcerans, the causative agents of
leprosy and buruli ulcers in humans, are also effectively killed by TMC207 [Ji
et al., 2006a, Ji et al., 2006b]. In a murine model of tuberculosis TMC207 as
monotherapy proved at least as active as the combination of the first-line an-
tibiotics rifampin, isoniazid and pyrazinamide [Andries et al., 2005]. TM207
showed strong synergy with pyrazinamide, this combination therapy renders
almost all infected mice culture-negative after two months of treatment [An-
dries et al., 2005,Ibrahim et al., 2007,Lounis et al., 2006]. This indicates that a
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therapy including TMC207 and pyrazinamide could have the potential to signif-
icantly shorten tuberculosis treatment. The long half-life of TMC207 [Andries
et al., 2005] and the low proportion of resistant development to TMC207 [An-
dries et al., 2005,Huitric et al., 2010] are favorable characteristics for usage in
intermittent therapy of tuberculosis. The combination of TMC207, rifapentine
and pyrazinamide administered intermittently was found more active than a
daily regimen of the current first-line therapy isoniazid, rifampin and pyrazi-
namide [Veziris et al., 2009], raising the possibility of developing a new fully
intermittent short-course regimen for the therapy of tuberculosis.
1.1.2 The mycobacterial respiratory chain
Electrons can enter the respiratory chain via oxidation of NADH using NADH
dehydrogenase. Most mycobacteria possess two types of NADH dehydrogenases
in their respiratory chain. The proton-translocating type I NADH dehydro-
genase apparently is not essential for growth of M. tuberculosis [Rao et al.,
2008, Sassetti et al., 2003]. Alternatively, a non-proton-translocating type II
NADH dehydrogenase serves as the primary NADH dehydrogenase for NADH
oxidation and utilizes menaquinone as an electron acceptor (Fig. 1.1). After
accepting electrons from the type II NADH dehydrogenase, menaquinol can be
oxidized either by cytochrome bc1 reductase (subunits QcrA-C), which then
transfers the electrons to an aa3-type cytochrome c oxidase (subunits CtaC-
F) [Matsoso et al., 2005], or directly by cytochrome bd oxidase (subunits CydA-
B) [Kana et al., 2001] (Fig. 1.1, for a review see [Cox & Cook, 2007]). The
route via the cytochrome bc1 reductase-cytochrome c oxidase supercomplex is
bioenergetically favorable as electron transport and the reduction of O2 at the
aa3-type cytochrome is coupled with proton translocation across the membrane.
However, cytochrome bd oxidase displays a higher affinity for oxygen and is thus
used under O2-limiting conditions [Kana et al., 2001], whereas the cytochrome
aa3-type enzyme is the predominant terminal electron acceptor during aerobic
growth [Shi et al., 2005]. ATP synthase utilizes the proton motive force across
the cytoplasmatic membrane for synthesis of adenosine-5′-triphosphate (ATP)
from adenosine phosphate (ADP) and inorganic phosphate (Pi). The enzyme
consists of a cytosolic F1 part (subunits α3β3γδε) and the membrane-embedded
F0 entity (subunits ab2c10−15), which are responsible for catalysis of ATP syn-
thesis and for proton flow, repectively (Fig. 1.1). ATP synthase is evolutionarily
strongly conserved among prokaryotes and eukaryotes.
In contrast to several other bacteria, which can produce sufficient ATP by
substrate-level phosphorylation and tolerate deletion of ATP synthase [Jensen
4 Chapter 1. General introduction
 
S
d
h
C
SdhB
SdhA
 
 
F
F
N
a
rI
NarH
NarG
N
a
rK
2
NADH
C
y
d
A
C
y
d
B
 C
ta
C
C
ta
F
C
ta
E
C
ta
D
Q
cr
C
Q
cr
A
Q
cr
B
 
NDH-2
MK MKH
NAD
Succinate
Fumarate
MKH
MK
1/2 O
MKH
NO
NO
ADP+Pi ATP
MK
Phenothiazines
TMC207
Pyrazinamide 
H+
H+
H+
H+ H+
H+H+
H+
H+
H2O2
H2O
2
2 
2
3
-
2
-
1
o
1/2 O2
Cytoplasm
Periplasm
H+
+
MKH
MK
2
Figure 1.1: Schematic view of the mycobacterial respiratory chain. The menaquinone (MK)
pool can be reduced by either NDH-2 (yellow) or via succinate (dark blue) and oxidized
by either a cytochrome bc1 (dark green)/cytochrome aa3 (pink) super-complex or by the
cytochrome bd oxidase (light green). The proton motive force is used by ATP synthase (light
blue) for the production of ATP. The nitrate reductase and transporter system is shaded
in brown. The type-I-proton-translocating NADH dehydrogenase, which is not essential for
growth, is not shown. Small-molecule compounds, which block respiratory ATP production
and act bactericidally on replicating and dormant mycobacteria, are depicted in red (adapted
from [Bald & Koul, 2010].
& Michelsen, 1992], ATP synthase has been proven to be essential for optimal
growth in M. tuberculosis [Sassetti et al., 2003] and for growth on fermentable
and nonfermentable carbon sources inMycobacterium smegmatis [Tran & Cook,
2005]. This enzyme in principle can also function in the reverse direction as
a proton pump to maintain a proton motive force under condicitons of low
oxygen tension or low nutrient availability [von Ballmoos et al., 2009]. However,
ATP synthase from several bacteria displays only very limited ATP hydrolysis
activity, for example in Paracoccus denitrificans [Harris et al., 1977], Bacillus
subtilis [Hicks et al., 1994] Thermus thermophilus [Nakano et al., 2008] and
Mycobacterium phlei [Higashi et al., 1975].
TMC207 specifically binds to subunit c of ATP synthase [Koul et al., 2007].
During enzymatic catalysis, this oligomeric subunit, together with subunits ε
and γ, rotates relative to subunits α3β3δab and in this way couples proton flow
to the synthesis of ATP [Boyer, 1993, Junge et al., 1997]. Protons enter from
the periplasmic space via an entry channel in subunit a and are then transferred
to an essential acidic residue in the membranespanning part of subunit c (Fig.
1.2). After a close to 360◦ rotation of the cylindrical subunit c oligomer relative
to subunit a, the protons are released on the cytosolic side of the membrane via
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Figure 1.2: Schematic view of ATP synthase and proton flow during ATP synthesis. During
the synthesis of ATP, the oligomeric subunit c (dark gray), together with subunits γ and ε
(red), rotates relative to the other subunits of the ATP synthase complex.
an exit channel in subunit a [Diez et al., 2004,Vik & Antonio, 1994]. Mutations
in subunit c conferring resistance to TMC207 suggest a binding site in the
central region of subunit c, close to the essential acidic residue [Andries et al.,
2005,Huitric et al., 2007,Huitric et al., 2010,Koul et al., 2007, Petrella et al.,
2006].
1.2 Outline of the thesis
Chapter 2
describes the investigation of the selectivity of TMC207 towards mycobacterial
ATP synthase compared with that towards mitochondrial ATP synthase. In a
sub-cellular mycobacterial membrane assay and human mitochondria the effect
of TMC207 on ATP synthesis was determined. The study reveals that human
mitochondrial ATP synthase displayed more than 20, 000-fold lower sensitivity
for TMC207 compared to that of mycobacterial ATP synthase, indicating that
the compound is highly specific for mycobacteria and unlikely to be toxic for
mammalian cells. Our results illustrate that ATP synthase is a promising drug
target, despite the fact that the enzyme is conserved among prokaryotes and
eukaryotes.
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Chapter 3
describes the characterization of the physiological role of ATP synthase in slow-
growing mycobacterial strains. ATP synthase in inverted membrane vesicles
from the slow-growing model strain M. bovis BCG is active in ATP synthe-
sis, but blocked in ATP hydrolysis direction. These results suggest that ATP
synthase is needed for synthesis of ATP, not for maintenance of the proton mo-
tive force. For the development of new antimycobacterial drugs acting on ATP
synthase, screening for ATP synthesis inhibitors, but most likely not for ATP
hydrolysis blockers, can be regarded as a promising strategy.
Chapter 4
describes the mode of binding between TMC207 and mycobacterial ATP syn-
thase. Factors that can potentially influence binding between the compound
and its target, such as the proton motive force, the pH value and buffer ionic
strength, were investigated using biochemical assays and binding studies. Inde-
pendent of environmental conditions such as the local pH and the proton motive
force, TMC207 displays high affinity for its target. The drug binds to a defined
binding site in ATP synthase, most likely blocking conformational changes as-
sociated with proton flow. These properties, combined with the essentiality
of the target, may in part explain the exceptional ability of this compound to
efficiently kill mycobacteria in different microenvironments.
Chapter 5
describes the metabolic response of a slow-growing mycobacterium, M. bovis
BCG, to inhibition of ATP synthase by TMC207. Elucidating the metabolic
response to antibiotic action can reveal points of vulnerability in bacterial
metabolism. In the presence of TMC207 the major ATP consuming pathways,
such as nucleotide synthesis, DNA synthesis and protein synthesis, were down-
regulated, indicating a general response to conserve cellular energy. Activation
of the glyoxylate cycle and upregulation of enzymes of β-oxidation indicates a
shift to lipid metabolism. The observed downregulation of ATP consumption
may in part explain the delayed bactericidal effect of TMC207.
Chapter 6
describes the isolation of ATP synthase from a slow-growing mycobacterial
strain. The isolated detergent-solubilised enzyme displays low ATP hydrolysis
References 7
activity and is sensitive to N,N ′-dicyclohexyl-carbodiimide. As mycobacterial
ATP synthase has recently been validated as target of new class of candidate
drugs against tuberculosis, the diarylquinolines, availability of isolated ATP
synthase may help to investigate interaction between drug and target. More-
over, the isolated enzyme may be used to shed light on the unusual subunit
composition of mycobacterial ATP synthase, as suggested by genomic data.
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Abstract
The diarylquinoline TMC207 kills Mycobacterium tuberculosis by specifically
inhibiting ATP synthase. We show here that human mitochondrial ATP syn-
thase (50 % inhibitory concentration [IC50] of > 200 µM) displayed more than
20,000-fold lower sensitivity for TMC207 compared to that of mycobacterial
ATP synthase (IC50 of 10 nM). Also, oxygen consumption in mouse liver and
bovine heart mitochondria showed very low sensitivity for TMC207. These
results suggest that TMC207 may not elicit ATP synthesis-related toxicity in
mammalian cells. ATP synthase, although highly conserved between prokary-
otes and eukaryotes, may still qualify as an attractive antibiotic target.
2.1 Introduction
A new series of compounds, the diarylquinolines, was reported to be highly ac-
tive against Mycobacterium tuberculosis [Andries et al., 2005]. TMC207, the
lead compound of the diarylquinoline series, displays MICs of 30 nM for M.
tuberculosis and 15 nM for Mycobacterium smegmatis. We recently demon-
strated that TMC207 targets ATP synthase, the enzyme responsible for ATP
production by oxidative phosphorylation [Koul et al., 2007]. The inhibition of
ATP synthase by TMC207 was highly specific, with a 50 % inhibitory concen-
tration (IC50) for this enzyme corresponding to the MIC for bacterial growth
inhibition [Koul et al., 2007]. This compound, which efficiently kills replicating
as well as dormant mycobacteria [Koul et al., 2008,Rao et al., 2008], is currently
in clinical development in phase IIb trials in patients with multidrug-resistant
tuberculosis.
An important factor to consider for a new antibacterial drug is the lack of
a eukaryotic homologue of the target, as inhibition of a homologous enzyme
could lead to toxicity and safety concerns in humans. In case of TMC207, the
target enzyme ATP synthase is essential for survival in higher organisms, as
it supplies cells with the bulk of their ATP via oxidative phosphorylation [von
Ballmoos et al., 2008]. ATP synthase is evolutionarily strongly conserved among
prokaryotes and eukaryotes. Universally, ATP synthesis is coupled to the flow of
protons from the intercristae region in mitochondria and the periplasmic space in
bacteria to the mitochondrial matrix and the bacterial cytoplasm, respectively.
Subunit c of ATP synthase, forming a membrane-spanning oligomer, is essential
for this proton transport [Fillingame & Dmitriev, 2002].
TMC207 binds to subunit c of mycobacterial ATP synthase [Koul et al.,
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2007]. Several natural compounds, such as oligomycin and venturicidin, are
known to block ATP synthase action by interaction with subunit c. However,
these compounds are not selective and inhibit ATP synthase not only in bacteria
but also in mitochondria [Matsuno-Yagi & Hatefi, 1993a,Matsuno-Yagi & Hatefi,
1993b]. This lack of selectivity prevents their clinical usage due to toxicity issues
and fatality concerns. Mitochondrial toxicity is a major concern in the clinical
development of new drugs, as it may lead to disease conditions, such as pan-
creatitis, peripheral neuropathy, and cardial or skeletal myopathies [Amacher,
2005,Wallace & Starkov, 2000].
Hence, it is of key importance to investigate the selectivity of TMC207 to-
wards mycobacterial ATP synthase compared with that towards mitochondrial
ATP synthase.
2.2 Results and discussion
Mycobacterium smegmatismc2155 was cultured and inverted membrane vesicles
were prepared as described [Andrew & Roberts, 1993,Koul et al., 2007]. The
human ovarian cancer cell line OVCAR3 was grown in Dulbecco’s modified Ea-
gle’s medium containing 10 % fetal bovine serum and 100 units mL−1 penicillin-
streptomycin. Mitochondria and submitochondrial particles (SMPs) were iso-
lated and prepared according to methods outlined previously [Corte´s-Herna´ndez
et al., 2007,Garc´ıa et al., 2000,Wang et al., 2007]. ATP synthesis activity by
human mitochondria and mycobacterial membrane vesicles was measured as de-
scribed previously [Corte´s-Herna´ndez et al., 2007,Garc´ıa et al., 2000,Koul et al.,
2007]. Mouse liver mitochondria and mitoplasts were isolated and prepared from
M18 mice as described previously [Bunney et al., 2001,Matsuno-Yagi & Hatefi,
1993a]. The method of [Smith, 1967] was used to isolate bovine heart mito-
chondria. Mitochondria or mitoplast oxygen consumption rates were monitored
according to the methods from references [Ciapaite et al., 2005] and [Mildaziene
et al., 2002].
First, we monitored the effect of TMC207 on ATP synthesis in isolated
mitochondria from a human cancer cell line. No effect of TMC207 on ATP
production was observed at nanomolar concentrations; extremely high concen-
trations of 200 µM compound lead to approximately 35 % inhibition (Fig. 2.1A).
N,N ′-dicyclohexyl-carbodiimide (DCCD; 5 µM) and oligomycin (1 µM), two
nonselective ATP synthase inhibitors, both suppressed ATP synthesis by > 90
% (Fig. 2.1A). In contrast, ATP synthase within inverted membrane vesicles of
M. smegmatis was efficiently inhibited by nanomolar concentrations of TMC207.
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Figure 2.1: Effect of TMC207 on ATP synthesis by mitochondria from a human cell line.
ATP synthesis in the presence of TMC207 was measured for mitochondria (250 µg mL−1)
and SMPs (150 µg mL−1) from a human cancer cell line (A) and compared to that for
inverted membrane vesicles of Mycobacterium smegmatis (B). Samples were incubated at 25
◦C for 1 h in the presence of an ADP-regenerating system, and produced ATP was quantified
spectrophotometrically by monitoring oxidation of glucose-6-phosphate with NADP+. As
controls, DCCD (100 µM for M. smegmatis and 5 µM for human mitochondria and SMPs)
and oligomycin (1 µM) were used.
Half-maximal inhibition was achieved with 10 nM TMC207; virtually complete
inhibition was achieved in the presence of 100 nM compound (Fig. 2.1B). From
the IC50s obtained for human (IC50, > 200 µM) and mycobacterial (IC50, 0.01
µM) ATP synthase, a high selectivity index of > 20, 000 for TMC207 was calcu-
lated. TMC207 has a strongly hydrophobic core structure [Andries et al., 2005]
and may get trapped in the mitochondrial outer membrane. For this reason,
we also investigated the effect of TMC207 on SMPs, mitochondria from which
the outer membrane was removed by sonication treatment. However, as ob-
served for whole mitochondria, human SMPs showed only very low sensitivity
for TMC207, with an IC50 of > 200 µM (Fig. 2.1A). Thus, the lack of sus-
ceptibility of human ATP synthase cannot be accounted for by a permeability
barrier function of the mitochondrial outer membrane.
We then determined the effect of TMC207 on oxygen consumption by mito-
chondria freshly isolated from mouse liver and bovine heart tissue. In isolated
mitochondria, any inhibition of ATP synthase or the respiratory chain enzyme
complexes will cause decreased oxygen consumption. Here, for both mouse liver
2.2. Results and discussion 17
5 25 50 10
0
17
5
O
lig
om
yc
in
0
25
50
75
100
TMC207 (µM)
Mouse mitochondria
Mouse mitoplasts
Bovine mitochondria
R
el
a
ti
v
e 
in
h
ib
it
io
n
 (
%
)
Figure 2.2: Effect of TMC207 on respiratory function in mitochondria isolated from mouse
and bovine tissue. Oxygen consumption coupled to ATP synthesis in the presence of TMC207
was measured for mitochondria from mouse liver, mitoplasts from mouse liver, and mitochon-
dria from bovine heart (each at a final protein concentration of 1 mg mL−1). The oxygen
concentration was measured using a Clark electrode at 37 ◦C in a medium with 20 mM Tris-
HCl, pH 7.3, 85 mM KCl, 5 mM KH2PO4, 2.3 mM MgCl2, 25 mM creatine, and 25 mM
phosphocreatine in the presence of an ADP-regenerating system and the indicated concentra-
tions of TMC207. The membrane was energized by an addition of succinate, and complex I
was inhibited by rotenone. Inhibition of ATP synthase and respiratory chain enzymes was
determined as a decrease in the state III oxygen consumption rate. As a control, oligomycin
(0.6 µM) was used. Each graph shows mean values of three independent experiments with
standard deviations.
and bovine heart mitochondria, no significant effect on oxygen consumption was
measured for TMC207, even in the presence of high (175 µM) concentrations
(Fig. 2.2). As a control, oligomycin efficiently inhibited oxygen consumption by
> 80 % in mouse liver and > 50 % in bovine heart mitochondria. Furthermore,
ATP synthase and respiratory function in mitoplasts, mouse liver mitochondria
from which the outer membrane was removed by mild osmotic shock, were not
significantly inhibited by TMC207 (Fig. 2.2).
Taken together, mitochondria from human cells, mouse liver and bovine
heart show only very low sensitivity for TMC207. The high selectivity index
for TMC207 indicates that the compound is very specific and unlikely to induce
target-based toxicity in mammalian cells. In drug development, compounds with
a selectivity index of > 1, 000 are regarded as promising candidates for clinical
development. TMC207 may thus be the first highly selective ATP synthase
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inhibitor with the potential to treat a bacterial infection. In a phase I clinical
study with healthy volunteers, short-term administration of TMC207 in humans
was found to be safe and well tolerated without serious adverse effects [Andries
et al., 2005]. Our results provide the basis for a rational explanation of the
preliminary clinical safety observed with this compound.
It has been previously shown that the point mutations A63P and I66M in
subunit c (Fig. 2.3) lead to acquired resistance inM. tuberculosis [Andries et al.,
2005, Petrella et al., 2006]. Furthermore, in certain mycobacterial species like
M. xenopi, M. shimoidei and M. novocastrense, the naturally occurring genetic
polymorphism of A63M results in intrinsic resistance [Huitric et al., 2007]. Dock-
ing studies based on binding energy minimization have suggested that E61, A63
and I66 contribute to a binding pocket for TMC207 in the membrane-spanning
region of subunit c [de Jonge et al., 2007]. Amino acid changes or natural poly-
morphisms in this binding pocket may cause steric hindrance and thus prevent
efficient binding of the drug. Interestingly, ATP synthases from human, mouse,
and bovine mitochondria also display a methionine at position 63 of subunit
c, and this polymorphism on its own may account for the lack of inhibition of
ATP synthase in mitochondria from these organisms. Although in humans three
different isoforms of subunit c are known [Kramarova et al., 2008], no tissue-
specific sensitivity for TMC207 can be expected, as these isoforms represent the
same mature protein and differ only in the mitochondrial import sequence.
Targeting the bacterial energy metabolism, despite the fact that the enzymes
involved are conserved among prokaryotes and eukaryotes, is a valid approach
and may help to combat the increased emergence of drug resistance. More
generally, our results illustrate that in drug discovery, a protein should not be
disregarded a priori as a potential drug target because of the existence of a
human homologue.
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Figure 2.3: Multiple sequence alignment for subunit c of ATP synthase. Amino acid se-
quences of ATP synthase subunit c from mycobacteria and eukaryotic species are compared.
Species abbreviations: M.tub, M. tuberculosis (Swiss-Prot accession no. Q10598); M.sme,
M. smegmatis (EMBL accession no. AJ862722); M.xen, M. xenopi (GenBank accession no.
DQ306893); H.sap, Homo sapiens (residue 60 to 136; RefSeq accession no. NM 001002027);
B.tau, Bos Taurus (bovine, residue 60 to 136; RefSeq accession no. NP 788822); and M.mus,
Mus musculus (mouse, residue 60 to 136; RefSeq accession no. NM 007506). For comparison,
the two transmembrane helices found in the structure of the Escherichia coli enzyme are indi-
cated below. The N-terminal part of the mitochondrial precursor sequence for the bovine and
mouse subunit c is not shown. Amino acid residues found to be important for drug-sensitivity
inM. tuberculosis (positions 63 and 66, numbering forM. tuberculosis) are indicated by boxes.
The glutamic acid residue E61 is an essential residue for proton translocation.
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Abstract
ATP synthase is a validated drug target for treatment of tuberculosis, and
ATP synthase inhibitors are promising candidate drugs for treatment of infec-
tions caused by other slow-growing mycobacteria, such asMycobacterium leprae
and Mycobacterium ulcerans. ATP synthase is an essential enzyme in energy
metabolism of Mycobacterium tuberculosis; however, no biochemical data are
available to characterize the role of ATP synthase in slow-growing mycobacterial
strains. Here, we show that inverted membrane vesicles from the slow-growing
model strain Mycobacterium bovis BCG are active in ATP synthesis, but ATP
synthase displays no detectable ATP hydrolysis activity and does not set up a
proton-motive force (PMF) using ATP as a substrate. Treatment with methanol
as well as PMF activation unmasked the ATP hydrolysis activity, indicating that
the intrinsic subunit ε and inhibitory ADP are responsible for suppression of
hydrolytic activity. These results suggest that the enzyme is needed for syn-
thesis of ATP, not for maintenance of the PMF. For the development of new
antimycobacterial drugs acting on ATP synthase, screening for ATP synthesis
inhibitors, but not for ATP hydrolysis blockers, can be regarded as a promising
strategy.
3.1 Introduction
Infections by Mycobacterium tuberculosis account for nearly 2 million deaths
per year and are the predominant cause of death in HIV patients [Check, 2007].
Although first line antibiotics are available for treatment of tuberculosis, multi-
drug resistant strains of M. tuberculosis have emerged and pose a global health
challenge [Dye, 2009,Mandavilli, 2007]. Development of novel antibacterial com-
pounds as well as the discovery and validation of new target proteins are of key
importance to improve current tuberculosis treatment [Bald & Koul, 2010,Sas-
setti et al., 2003].
In recent years, mycobacterial ATP synthase has been identified as the target
of diarylquinolines, a new class of potent antimycobacterial drugs [Andries et al.,
2005,Koul et al., 2007]. Chemical inhibition of ATP synthesis by diarylquino-
lines strongly decreased cellular ATP levels, leading to bacterial killing [Koul
et al., 2007, Koul et al., 2008, Rao et al., 2008]. Diarylquinolines lead com-
pound TMC207 displays pronounced target selectivity, with only an extremely
low effect on ATP synthesis in the human mitochondria [Haagsma et al., 2009].
In phase IIb clinical tests, TMC207 strongly decreased the count of CFUs in
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the sputum of patients with multi-drug-resistant tuberculosis, validating ATP
synthase as a target for the treatment of tuberculosis [Diacon et al., 2009].
Diarylquinolines have also been shown to effectively kill other mycobacterial
strains, such as Mycobacterium leprae and Mycobacterium ulcerans [Ji et al.,
2006a,Ji et al., 2006b].
ATP synthase is a multisubunit complex consisting of a membrane-embedded
F0 part (subunits ab2c10−15) and a cytosolic F1 moiety (α3β3γδε). The enzyme
can utilize the proton-motive force (PMF) across the bacterial cytoplasmatic
membrane for the synthesis of ATP (for a review, see [Boyer, 2002]). At low
PMF, for example in environments with limited oxygen concentrations, this
reaction can be reversed in several bacteria, which use the energy released from
hydrolysis of ATP to maintain a PMF [von Ballmoos et al., 2009]. However, ATP
synthases from several other bacteria display only very limited ATP hydrolysis
activity, for example in Paracoccus denitrificans [Harris et al., 1977], Bacillus
subtilis [Hicks et al., 1994], Thermus thermophilus [Nakano et al., 2008] and
Mycobacterium phlei [Higashi et al., 1975].
ATP synthase has been proven to be essential for optimal growth in M.
tuberculosis [Sassetti et al., 2003] and for growth on fermentable and nonfer-
mentable carbon sources in Mycobacterium smegmatis [Syroeshkin et al., 1995].
However, it is not known whether the observed essentiality stems from a need
for ATP synthase to produce ATP or to maintain the PMF. A number of known
inhibitors of ATP synthase, for example sodium azide and aurovertin, strongly
discriminate between the enzyme in ATP synthesis mode or in ATP hydrolysis
mode [Bald et al., 1998, Johnson et al., 2009, Syroeshkin et al., 1995]. In order
to understand diarylquinoline action and selectivity as well as for design of im-
proved compound derivates, an insight into the mode of action of mycobacterial
ATP synthase is required.
Previous results showed only very low, ‘latent’, ATP hydrolysis activity for
ATP synthase from M. phlei [Higashi et al., 1975]. However, this strain is a
fast-growing, saprophytic bacterium (generation time < 3 h), whereas the most
relevant pathogenic mycobacteria, such as M. tuberculosis,M. leprae and My-
cobacterium ulcerans as well as the vaccine strain M. bovis Bacillus Calmette-
Gue´rin (BCG) are slow growers with a generation time > 15 h and with signif-
icantly different energy requirements [Beste et al., 2009,Cook et al., 2009]. No
data on ATP synthase functioning are reported for slow-growing mycobacteria,
in part due to their extremely thick cell envelope [Hoffmann et al., 2008], which
makes preparation and handling of membrane vesicles difficult.
In this study, we investigated ATP synthase in membrane vesicles of a slow-
growing Mycobacterium, M. bovis BCG, as well as in a fast-growing model
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strain, M. smegmatis.
3.2 Materials and methods
3.2.1 Bacterial strains and growth conditions
Mycobacterium bovis BCG Copenhagen and M. smegmatis mc2155 were kindly
provided by B.J. Appelmelk, Department of Molecular Cell Biology & Immunol-
ogy, VU University Medical Center Amsterdam, the Netherlands. Replicating
cultures of M. bovis BCG and M. smegmatis were grown in Middlebrook 7H9
broth (Difco) with 10 % Middlebrook albumin dextrose catalase enrichment
(BBL) and 0.05 % Tween-80 at 37 ◦C to the late exponential phase.
For growth under low-oxygen conditions, M. bovis BCG was cultured in a
gradual oxygen-depletion model [Wayne & Hayes, 1996] using Middlebrook 7H9
broth (Difco) with 10 % Middlebrook oleic BBL and 0.05 % Tween-80 at 37 ◦C.
Cells were harvested after 7 days in nonreplicating persistence-1 phase [Wayne
& Hayes, 1996].
3.2.2 Preparation of inverted membrane vesicles (IMVs)
Cells of M. bovis BCG were pelleted by centrifugation at 6000 g for 20 min
and washed once with Phosphate-buffered saline (PBS, pH 7.4). Five grams
of cells (wet weight) were resuspended in 10 mL of 50 mM MOPS-KOH (pH
7.5), 2 mM MgCl2 including protease inhibitors (complete, EDTA free; protease
inhibitor cocktail tablets from Roche). Lysozyme (10 mg mL−1), 1500 units of
deoxyribonuclease I (Invitrogen) and 15 mM MgCl2 were added and cells were
incubated with stirring at 37 ◦C for 1 h. Separation of this cell envelope digestion
procedure into a lysozyme preincubation step (1 mM MgCl2) and a subsequent
DNAse I digestion step (17 mM MgCl2) did not improve the results. The cells
were broken by four passages through a precooled French pressure cell at 20000
psi (Thermo Electron, 40K). The lysate was centrifuged at 6, 000 g and 4 ◦C for
20 min to remove unbroken cells. Two additional centrifugation steps at 6, 000 g
and 4 ◦C for 20 min were carried out to remove additional cell wall components.
The supernatant was centrifuged at 370, 000 g and 4 ◦C for 1 h and the pellet of
IMVs was washed with 50 mM MOPS-KOH (pH 7.5), 2 mM MgCl2. After the
second centrifugation step, the inverted membrane fraction was resuspended in
an appropriate volume of 50 mM MOPS-KOH (pH 7.5), 2 mM MgCl2.
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IMVs of M. smegmatis were prepared according to the procedure of [Koul
et al., 2007].
3.2.3 Assay for ATP-driven proton translocation
ATP-driven proton translocation into IMVs ofM. bovis BCG andM. smegmatis
was measured by decrease of 9-amino-6-chloro-2-methoxyacridine (ACMA) fluo-
rescence using a Cary Eclipse Fluorescence spectrophotometer (Varian Inc., Palo
Alto). IMVs (0.18 mg mL−1) were preincubated at 37 ◦C in 10 mM HEPES-
KOH (pH 7.5), 100 mM KCl, 5 mM MgCl2 containing 2µM ACMA and a
baseline was monitored for 5 min. The reaction was then started by adding 2
mM ATP, 5 mM succinate or 5 mM NADH. After 20 min, any proton gradient
was collapsed by the addition of 1µM SF6847. The excitation and emission
wavelengths were 410 and 480 nm, respectively. Other fluorophores reported
for PMF detection in bacteria, such as 9-aminoacridine (9AA) [Yoshimura &
Brodie, 1981] or Oxonol X [Bashford et al., 1979], did not yield interpretable
signals with either succinate or NADH as substrate (data not shown).
3.2.4 Assay of ATP synthesis
ATP synthesis was measured as described by [Haagsma et al., 2009]. Briefly,
IMVs (0.5 mg mL−1) from M. bovis BCG or M. smegmatis were incubated
in 10 mM HEPES-KOH (pH 7.5), 100 mM KCl, 5 mM MgCl2, 2 mM ADP,
20 mM KH2PO4, 100µM P
1,P5-di(adenosine-5′) pentaphosphate (Ap5A), 25.4
mM glucose, 11.8 U mL−1 hexokinase (Sigma) and protease inhibitors (com-
plete, EDTA-free; protease inhibitor cocktail tablets from Roche). Samples
(0.25 mL) were incubated at 37 ◦C with vigorous stirring in 18-mL flasks. For
the DCCD control, samples were preincubated with 100µM DCCD at room
temperature for 30 min. The reaction was initiated with 5 mM succinate. After
2 h, each reaction was stopped with 25 mM EDTA, followed by transfer to ice.
Samples were transferred to Eppendorf tubes, boiled for 5 min and centrifuged
(10, 000 g, 20 min) to remove denatured protein. In the supernatants, the syn-
thesized glucose-6-phosphate was oxidized by 2.5 mM NADP in the presence of
3 U mL−1 of glucose-6-phosphate dehydrogenase (Roche). NADPH formation
was monitored using a spectrophotometer at 340 nm.
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3.2.5 Assay of ATP hydrolysis
ATP hydrolysis activity was measured by quantifying the amount of phosphate
released [Bell & Doisy, 1920]. IMVs (0.5 mg mL−1) from M. bovis BCG or M.
smegmatis were incubated in 10 mM HEPES-KOH (pH 7.5), 100 mM KCl, 5
mM MgCl2 at 37
◦C. For the DCCD control, samples were preincubated with
100µM DCCD at room temperature for 30 min. The reaction was initiated by
2 mM ATP. After 30 min, the reaction was quenched by the addition of 2.4%
(w/v) trichloroacetic acid and the membranes were pelleted by centrifugation
at 20800 g and 4 ◦C for 15 min.
3.2.6 Activation of ATP hydrolysis activity
Activation by methanol: IMVs (0.5 mg mL−1) were incubated with 17,% or
25,% methanol. ATP hydrolysis was assayed as described earlier.
Activation by PMF: IMVs (2.5 mg mL−1) were incubated in the presence of
10 mM succinate to establish a PMF at 37 ◦C for 10 min. A mixture of
malonate and ATP (final concentrations are, respectively, 50 mM and 2
mM) was added and the incubation was quenched by the addition of 2.4,%
(w/v) trichloroacetic acid after 2.5 min. ATP hydrolysis was assayed as
described earlier.
Activation by trypsin: IMVs (0.5 mg mL−1) were incubated with trypsin at
30 ◦C for 10 min. Mycobacterium bovis BCG was treated with 90 or 750
U mL−1 of trypsin, while M. smegmatis was treated with 90 U mL−1 of
trypsin. The reaction was terminated by the addition of trypsin inhibitor
(1.5 mg of inhibitor per 1.0 mg of trypsin). ATP hydrolysis assay was
performed as described earlier.
Activation by sulfite: IMVs (0.5 mg mL−1) were incubated with 10 mM sodium
sulfite. ATP hydrolysis was assayed as described earlier.
3.3 Results and discussion
3.3.1 Functional IMVs from M. bovis BCG
To investigate the role of mycobacterial ATP synthase, we prepared functionally
coupled IMVs from the slow-growingM. bovis BCG. This strain shares > 99.9%
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Figure 3.1: Energization of mycobacterial IMVs. Membrane vesicles from Mycobacterium
bovis BCG (A) and Mycobacterium smegmatis (B) were diluted to 0.18 mg mL−1 in PA4
buffer (pH 7.5), containing 2µM ACMA. Quenching of ACMA fluorescence was investigated
after the addition of a substrate (2 mM ATP, 5 mM NADH or 5 mM succinate). At the
indicated time point, 1µM of uncoupler SF6847 was added to collapse the proton gradient.
DNA sequence identity with M. tuberculosis and strongly resembles M. tuber-
culosis in terms of sensitivity to diarylquinolines [Huitric et al., 2007,Mattow et
al., 2001]. For comparison, we carried out the same set of experiments with the
fast-growing saprophyte M. smegmatis.
To cope with the extremely thick cell envelope of M. bovis BCG, we opti-
mized the preparation of IMVs in terms of the time and temperature of cell en-
velope digestion by lysozyme, number of French Press passages and subsequent
centrifugation steps (cf. Materials & methods). To confirm the functionality
of the IMVs produced, we tested their ability to set up a PMF with succinate
or NADH as external electron donor using ACMA as a fluorescence indicator.
Both succinate and NADH caused fluorescence quenching, which was eased after
the addition of an uncoupler, proving that the observed quenching was indeed
caused by the PMF (Fig. 3.1A). Quenching reached a maximum after ∼ 10
min (Fig. 3.1A), significantly slower than IMVs from Escherichia coli under
identical conditions (data not shown). This slow quenching may be caused by a
larger percentage of leaky IMVs. The lower PMF observed with NADH (11%
quenching) compared to succinate (39%) might be due to the partial detach-
ment of the membrane-associated type-II NADH-dehydrogenase (NDH-II), the
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main NADH-oxidizing enzyme of the respiratory electron transport chain in M.
bovis BCG [Boshoff et al., 2004,Weinstein et al., 2005]. From these results, it
can be concluded that the IMVs are functional. Similarly, IMVs from the fast-
growing M. smegmatis accepted both NADH and succinate as electron donor
(Fig. 3.1B).
3.3.2 ATP hydrolysis is blocked in M. bovis BCG and M.
smegmatis
We then investigated whether the IMVs can establish a PMF with ATP as a
substrate. No significant quenching was detected either for M. bovis BCG or for
M. smegmatis, even after an extended (> 30 min) incubation time (Fig. 3.1A
and B). The very small intensity decrease directly after ATP addition is due to
sample volume increase and is not reverted by addition of uncoupler.
Neither variation of the ATP/Mg2+ ratio (from 0.4:1 to 2:1), or variation of
the pH value (pH 5.5−8.0) nor preparation of IMVs fromM. bovis BCG cultured
in an oxygen depletion model (Wayne system) led to detectable quenching upon
ATP addition. These results indicate that mycobacterial ATP synthase is not
carrying out ATP-hydrolysis-driven proton transport.
To exclude the possibility that the observed lack of ATP-hydrolysis-driven
proton transport is caused by an extremely low number of ATP synthase mole-
cules in the mycobacterial membrane or by of the detachment of the extrinsic F1
part of ATP synthase, we compared the DCCD-sensitive activities in ATP syn-
thesis and ATP hydrolysis. As shown in Table 3.1, the IMVs from bothM. bovis
BCG and M. smegmatis were active in ATP synthesis with specific activities of
0.27 and 0.96 nmol min−1 mg−1, respectively. In contrast, we could not detect
any significant DCCD-sensitive ATP hydrolysis activity in IMVs from M. bovis
BCG. For M. smegmatis IMVs, DCCD-sensitive ATP hydrolysis activity was
detectable, but > 4-fold lower as compared to ATP synthesis (Table 3.1). For
an enzyme working with equal speed in both directions, the ATP hydrolysis ac-
tivity is expected to be higher than the synthesis activity, for example ∼ 10-fold
for ATP synthase from Bacillus PS3 [Bald et al., 1998,Bald et al., 1999]. This
effect is due to the presence of enzymes in leaky vesicles, unavoidably present
in IMV preparations, which can split ATP, but are unable to synthesize it.
Our results thus show that ATP synthase in both M. bovis BCG and M.
smegmatis is blocked in the ATP hydrolysis mode and is not able to generate
a PMF by hydrolyzing ATP. The essentiality of ATP synthase is thus based on
a function in the synthesis direction, most likely either for the production of
ATP, pH homeostasis, or for contributing to the NAD+/NADH redox balance.
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The task of PMF maintenance under low oxygen tensions is most probably
fulfilled by other membrane-protein complexes, such as by nitrate reductase
or by fumarate reductase acting in reverse [Schnorpfeil et al., 2001,Wayne &
Sohaskey, 2001].
Table 3.1: DCCD-sensitive ATP synthesis and ATP hydrolysis activities of mycobacterial
membrane vesicles.
Activity (nmol min−1 mg−1)
ATP synthesis ATP hydrolysis
M. bovis BCG 0.27± 0.17 Not detectable
M. smegmatis 0.96± 0.15 0.21± 0.32
ATP synthesis and ATP hydrolysis activities of inverted membranes from Mycobacterium bo-
vis BCG and Mycobacterium smegmatis were measured at 37 ◦C by, respectively, the glucose-
6-phosphate dehydrogenase method and inorganic phosphate release as described under 3.2
Materials and methods. The results shown represent the mean ± SD from three different
preparations.
3.3.3 Mechanism of ATP hydrolysis blockage in mycobac-
terial ATP synthase
In order to gain an insight into the mechanism of ATP hydrolysis blockage in
mycobacteria, we tested the effect of four different treatments reported to acti-
vate latent ATP hydrolysis activity in bacteria. Limited trypsin proteolysis is
reported to cleave the inhibitory intrinsic subunit ε and in this way activate ATP
hydrolysis [Bogin et al., 1970,Keis et al., 2006], while the addition of methanol
is thought to compromise hydrophobic interactions within ATP synthase [His-
abori et al., 1997]. Moreover, oxy-anions, for example sulfite, are reported to
remove inhibitory ADP and to uncouple ATP synthase function [Cappellini et
al., 1997,Pacheco-Moise´s et al., 2002]. Finally, membrane energization is known
to relieve ADP inhibition and to switch the conformation of subunit ε to a
noninhibitory state [Suzuki et al., 2003].
The ATP hydrolysis activity of IMVs of M. smegmatis was indeed activated
> 30-fold by trypsin (Table 3.2), indicating that subunit ε is an important deter-
minant for ATP hydrolysis blockage in this fast-grower. However, in case of M.
bovis BCG, trypsin treatment did not lead to significant activation (Table 3.2).
This lack of activation can be explained either by inaccessibility of the trypsin
cleavage site or by the presence of alternative inhibitory mechanisms. To further
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investigate ATP hydrolysis in M. bovis BCG, we tested the effect of methanol,
sodium sulfite, and PMF activation. Whereas sulfite slightly activated ATP
hydrolysis activity, both addition of methanol and membrane energization by
succinate led to more significant activation forM. bovis BCG, with the resulting
activity ∼ 10-fold higher than the ATP synthesis activity (Table 3.2).
The results suggest that ATP hydrolysis in both slow-growing as well as
fast-growing mycobacteria is regulated in a PMF-dependent manner, prevent-
ing excess ATP consumption under low oxygen tensions. Suppression of activity
appears to be more pronounced in the slow-grower, which may be an adaptation
to environments with a low energy supply and/or decreased oxygen tensions,
for example in remote parts of the mammalian lungs. Mycobacteria, requir-
ing oxygen for growth, but able to persist under anaerobic conditions, thus
utilize a similar mechanism of ATP hydrolysis inhibition as reported for the ob-
ligate aerobic bacteria P. denitrificans [Zharova & Vinogradov, 2003,Zharova &
Vinogradov, 2004] andMicrococcus luteus [Gru¨ber et al., 1994] and for the alka-
liphilic bacteria Bacillus firmus OF4 [Hicks & Krulwich, 1990] and Bacillus sp.
TA2.A1 [Keis et al., 2006]. Whereas in alkaliphilic bacteria subunit ε has been
pinpointed as the PMF-dependent regulator of ATP hydrolysis activity, in P.
denitrificans and related Alphaproteobacteria, recently a new intrinsic inhibitor
protein, termed subunit ζ was found [Morales-R´ıos et al., 2010]. However, as
database search did not reveal any homolgue of subunit ζ in mycobacteria, we
regard subunit ε as the most likely candidate for this regulatory task.
Table 3.2: Activation of ATP hydrolysis in membrane vesicles from Mycobacterium bovis
BCG and Mycobacterium smegmatis.
Activity (nmol min−1 mg−1)
Activator M. bovis BCG M. smegmatis
Trypsin (90 U mL−1) Not detectable 4.30± 0.90
Sulfite (10 mM) 0.80± 0.35 1.17± 0.75
Methanol (17%) 3.24± 0.52 0.33± 0.22
Succinate (10 mM) 1.82± 1.0 1.30± 0.20
Inverted membranes were preincubated with 90 U mL−1 trypsin or 10 mM succinate at,
respectively, 30 and 37 ◦C. Subsequently, 2 mM ATP was added and the initial rate of ATP
hydrolysis was measured by inorganic phosphate production as described under 3.2 Materials
and methods. The results shown represent ± SD from three different preparations.
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3.4 Conclusion
Our results show that mycobacterial ATP synthase is blocked in the ATP hy-
drolysis direction and also suggest that any potential small-molecule inhibitor
acting on mycobacterial ATP synthase should interfere with the ATP synthesis
reaction in order to be considered as a drug candidate. An approach as used
for the development of antiischemia drugs blocking ATP hydrolysis [Harmann
et al., 2004] is thus not expected to be a promising strategy for development of
new antimycobacterial drugs.
However, activation of the latent ATP hydrolysis activity may lead to de-
pleted cellular ATP levels and decrease the bacterias viability. Compounds that
can specifically relieve blockage of ATP hydrolysis may thus be potential drug
candidates. Experiments to clarify this point and to understand the molecular
mechanism of ATP hydrolysis blockage in slow-growing mycobacteria are under
way in our laboratory.
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Abstract
Infections with Mycobacterium tuberculosis are substantially increasing on a
worldwide scale and new antibiotics are urgently needed to combat concomi-
tantly emerging drug-resistant mycobacterial strains. The diarylquinoline
TMC207 is a highly promising drug candidate for treatment of tuberculosis.
This compound kills M. tuberculosis by binding to a new target, mycobacterial
ATP synthase. In this study we used biochemical assays and binding studies
to characterize the interaction between TMC207 and ATP synthase. We show
that TMC207 acts independent of the proton motive force and does not compete
with protons for a common binding site. The drug is active on mycobacterial
ATP synthesis at neutral and acidic pH with no significant change in affinity
between pH 5.25 and pH 7.5, indicating that the protonated form of TMC207
is the active drug entity. The interaction of TMC207 with ATP synthase can
be explained by a one-site binding mechanism, the drug molecule thus binds
to a defined binding site on ATP synthase. TMC207 affinity for its target de-
creases with increasing ionic strength, suggesting that electrostatic forces play
a significant role in drug binding.
Our results are consistent with previous docking studies and provide exper-
imental support for a predicted function of TMC207 in mimicking key residues
in the proton transfer chain and blocking rotary movement of subunit c during
catalysis. Furthermore, the high affinity of TMC207 at low proton motive force
and low pH values may in part explain the exceptional ability of this compound
to efficiently kill mycobacteria in different microenvironments.
4.1 Introduction
Tuberculosis causes approximately 2 million deaths per year and an estimated
1/3 of the world population harbors Mycobacterium tuberculosis in a dormant
or latent form [Dye & Williams, 2010, Russel et al., 2010]. Infections with
multidrug-resistant and extensively drug-resistant mycobacterial strains as well
as co-infection with HIV pose a global health challenge [Gandhi et al., 2010,
Mandavilli, 2007,World Health Organization, 2010]. Existing drug regimens
need to be administered for at least 6 months, and up to 24 months in case of
drug-resistant tuberculosis [Gandhi et al., 2010,Koul et al., 2011]. To counteract
development of drug-resistant strains and to shorten tuberculosis treatment the
discovery of new drugs, validation of new target proteins, and understanding of
drug/target interactions are essential [Bald & Koul, 2010,Koul et al., 2011,Ma
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Figure 4.1: (A) Structure formula of TMC207. (B) ATP synthase subunit composition
with subunit c in grey. A homology model of a subunit c monomer from Mycobacterium
tuberculosis is shown enlarged. The acidic residue Glu61, essential for proton transport, is
depicted in red. Point mutations that influence mycobacterial sensitivity for TMC207 are
indicated in colour.
et al., 2010].
Energy metabolism has emerged as a new target-pathway for development
of new anti-tubercular drugs [Bald & Koul, 2010, Zhang & Mitchison, 2003].
The diarylquinoline TMC207 (Fig. 4.1A) is a highly promising candidate for
treatment of drug-resistant tuberculosis and for shortening of tuberculosis treat-
ment [Andries et al., 2005, Ibrahim et al., 2007, Lounis et al., 2006]. TMC207
acts on a novel target, mycobacterial ATP synthase [Koul et al., 2007] and is
highly active on replicating as well as on dormant mycobacteria [Koul et al.,
2008,Rao et al., 2008]. In phase II clinical trials addition of TMC207 to stan-
dard therapy antibacterial regimens strongly accelerated conversion to a nega-
tive sputum culture as compared to placebo [Diacon et al., 2009]. TMC207 acts
in a highly selective manner, with only minimal effect on human ATP synthase
and only minor side effects in human patients [Andries et al., 2005,Diacon et
al., 2009,Haagsma et al., 2009].
ATP synthase is a ubiquitous key enzyme in energy metabolism of virtually
all cells that utilizes the energy stored in a trans-membrane electrochemical
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potential difference of a coupling ion for production of ATP [Junge et al., 2009].
In mycobacteria, ATP synthase has been proven essential for growth on both
fermentable as well as non-fermentable carbon sources [Tran & Cook, 2005].
Bacterial ATP synthase is composed of a membrane-embedded F0 sector with
the subunit composition a1b2c10−15 and a hydrophilic F1 part, consisting of
subunits a3β3γδε (Fig. 4.1B). Proton flow through F0 triggers rotation of the
oligomeric subunit c ring that is coupled to rotation of the γ subunit within the
(αβ)3 hexamer of F1 and finally drives synthesis of ATP [Boyer, 1993,Diez et al.,
2004,Noji et al., 1997]. A significant step in proton transport is proton binding
to an essential acidic residue in the central, trans-membrane part of subunit
c [Pogoryelov et al., 2010]. TMC207 binds to purified mycobacterial subunit
c [Koul et al., 2007] and mycobacterial sensitivity for TMC207 is influenced by
point mutations located in the vicinity of the acidic residue in subunit c (Glu61
in M. tuberculosis, Fig. 4.1B) [Andries et al., 2005,Huitric et al., 2007,Huitric
et al., 2010,Koul et al., 2007,Petrella et al., 2006]. These findings suggest that
TMC207 may bind in that central, mostly hydrophobic part of subunit c. Based
on docking studies it has been proposed that TMC207 binds at the interface
of subunits c and subunit a [de Jonge et al., 2007]. The drug is predicted
to mimic a conserved basic residue in the proton transfer chain, arginine186,
subsequently interfering with the rotary movement of subunit c. [de Jonge et
al., 2007]. However, no high-resolution structure is available for mycobacterial
ATP synthase or its subunits. Moreover, biochemical data on TMC207/target
interaction to test the predictions from the docking studies are scarce.
In the present report we used biochemical assays and binding studies to
investigate the mode of binding between TMC207 and mycobacterial ATP syn-
thase. We study factors potentially influencing drug/target interaction, such as
the proton motive force, the pH value and buffer ionic strength. The results are
correlated with proposed models for the TMC207 binding site and discussed in
view of TMC207 being active in different microenvironments.
4.2 Materials and methods
4.2.1 Bacterial strains and growth conditions
Mycobacterium smegmatis mc2155 was kindly provided by B.J. Appelmelk,
Department of Molecular Cell Biology & Immunology, VU University Medi-
cal Center Amsterdam, the Netherlands. Replicating cultures of M. smegmatis
were grown in Middlebrook 7H9 broth (Difco) with 10% Middlebrook albumin
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dextrose catalase enrichment (BBL) and 0.05% Tween-80 at 37 ◦C to the late
exponential phase.
4.2.2 Preparation of inverted membrane vesicles
Inverted membrane vesicles (IMVs) ofM. smegmatis were prepared as described
previously [Koul et al., 2007]. Briefly, cells were pelleted by centrifugation at
5, 000 g for 20 min and washed once with Phosphate-buffered saline (PBS, pH
7.4). Five grams of cells (wet weight) were resuspended in 10 mL of 50 mM
MOPS-KOH (pH 7.5), 2 mM MgCl2 including protease inhibitors (complete,
EDTA free; protease inhibitor cocktail tablets from Roche). Lysozyme (1.2 mg
mL−1), 1500 units of deoxyribonuclease I (Invitrogen) and 13 mM MgCl2 were
added and cells were incubated with stirring at room temperature for 45 min.
The cells were broken by three passages through a pre-cooled French pressure
cell at 20, 000 psi (Thermo Electron, 40K). The lysate was centrifuged at 5, 000 g
and 4 ◦C for 20 min to remove unbroken cells. The supernatant was centrifuged
at 370, 000 g and 4 ◦C for 1 h and the pellet of IMVs was washed with 50 mM
MOPS-KOH (pH 7.5), 2 mM MgCl2. After the second centrifugation step, the
inverted membrane fraction was resuspended in an appropriate volume of 50
mM MOPS-KOH (pH 7.5), 2 mM MgCl2.
4.2.3 Assay of ATP synthesis
ATP synthesis activity was measured as described previously [Haagsma et al.,
2009] with the modifications described below. IMVs (1 mg mL−1) were in-
cubated in either 50 mM MES-KOH (pH 5.25) or 50 mM MOPS-KOH (pH
6.0-7.5) containing 2 mM MgCl2, 2 mM ADP, 20 mM KH2PO4, 100µM P
1,P5-
di(adenosine-5′) pentaphosphate (Ap5A), 25.4 mM glucose, 11.8 U mL−1 hexok-
inase (Sigma) and protease inhibitors (complete, EDTA-free; protease inhibitor
cocktail tablets from Roche). To manipulate the proton motive force samples
were supplemented with varying concentrations of uncoupler SF6847. Sam-
ples (0.25 mL) were incubated with vigorous stirring in 18-mL flasks at 37 ◦C.
The concentration of NADH to initiate the reaction was varied between 5-15
mM. After 1 h, each reaction was stopped with 25 mM EDTA, followed by
transfer to ice. Samples were transferred to Eppendorf tubes, boiled for 5 min
and centrifuged (10, 000 g, 20 min) to remove denatured protein. In the super-
natants, the synthesized glucose-6-phosphate was oxidized by 2.5 mM NADP
in the presence of 3 U mL−1 of glucose-6-phosphate dehydrogenase (Roche).
NADPH formation was monitored using a spectrophotometer at 340 nm. The
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50% inhibitory concentrations (IC50s) were determined using GraphPad Prism
version 5.00 for Macintosh, GraphPad Software, San Diego California USA. The
data were fitted with a model describing a one-site binding hyperbola.
4.2.4 BIAcore binding studies
Binding studies using Surface Plasmon Resonance technology were carried out
using a BIAcore 2000 machine with a carboxymethyl (CM-5) analytical chip. An
amine-analog of TMC207, wich carries an amino group instead of the bromine
[Koul et al., 2007], was bound to the chip at 25 ◦C as follows. 30µL of an equimo-
lar mixture of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(EDC) and N-hydroxysuccinimide (NHS) was used to activate the carboxy-
methyl surface of the chip. Subsequently, 30µL of the TMC207 amine analogue
(50µM) in 10 mM Hepes-KOH (pH 7.5), 2 mM MgCl2, 150 mM NaCl was
bound to the activated chip at a flow rate of 2µL min−1. Non-reacted activated
EDC/NHS on the chip surface was blocked by the infusion of 50µL of 1 M
ethanolamine.
Subunit c from Mycobacterium tuberculosis was purified as described in
previously [Koul et al., 2007]. The purified subunit c (13µM) was injected onto
the compound-linked Biacore chip at a flow rate of 30µL min−1 in 10 mM
Hepes-KOH (pH 7.5), 2 mM MgCl2, 0.5% Triton X-100 containing 50 mM,
150 mM or 300 mM NaCl (37 ◦C). Association, dissociation and equilibrium
dissociation constants were determined using GraphPad Prism version 5.00 for
Macintosh, GraphPad Software, San Diego California USA.
4.3 Results and discussion
4.3.1 TMC207 does not compete with protons for a com-
mon binding site
We investigated the effect of the proton motive force on ATP synthesis inhibition
by TMC207. TMC207 may interfere with ATP synthesis by competing with
protons for the same binding site on ATP synthase. A high proton motive
force may then outcompete TMC207 from its binding site, leading to reduced
drug/target binding. Conversely, a decreased proton motive force then would
lead to increased TMC207 binding. Moreover, the proton motive force not
only supplies the energy required for synthesis of ATP, but also constitutes
an important factor regulating the conformation of ATP synthase (for review
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Figure 4.2: ATP synthesis and inhibition by TMC207 at low proton motive force. (A)
Inverted membrane vesicles from Mycobacterium smegmatis were diluted to 0.18 mg mL−1
in buffer containing 2µM ACMA. To detect the proton motive force, quenching of ACMA
fluorescence was investigated after addition of 5 mM succinate in the presence of increasing
concentrations of the uncoupler SF6847. At the indicated time point, 1µM of uncoupler
SF6847 was added as control to collapse the proton gradient. (B) ATP synthesis by membrane
vesicles of M. smegmatis (1 mg mL−1) was measured in the presence of TMC207 and varying
concentrations of uncoupler SF6847 to modulate the proton motive force. Samples were
incubated at 37 ◦C for 1 h in the presence of an ADP-regenerating system, and produced
ATP was quantified spectrophotometrically by monitoring oxidation of glucose-6-phosphate
with NADP+. As a control, 100µM DCCD was added.
see [Feniouk & Yoshida, 2008]. Consequently, the affinity of several known ATP
synthase inhibitors depends significantly on the proton motive force [Bald et al.,
1998,Bald et al., 1999,Syroeshkin et al., 1995].
The proton motive force across inverted membrane vesicles (IMVs) of My-
cobacterium smegmatis was monitored with the ACMA quenching method as
in [Haagsma et al., 2010] and modulated using an uncoupler, SF6847 (Fig.
4.2A). As expected, with increasing uncoupler concentration the ATP synthesis
activity decreased in a dose-dependent manner, with < 10% residual activity
in the presence of 10µM uncoupler (Fig. 4.2B). We then tested three selected
concentrations of TMC207 (2.5 nM, 5 nM and 7.5 nM), which in the absence of
uncoupler decreased ATP synthesis activity by respectively 25%, 50% and 67%.
As depicted in Fig. 1B the inhibitory effect of TMC207 did not significantly
change at lower proton motive force. The drug concentrations for half-maximal
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inhibition (IC50) values were determined to 5.0-7.5 nM TMC207 for all uncou-
pler concentrations investigated. As a control, for membrane vesicles carrying
the resistance mutation D32V in subunit c [Andries et al., 2005], no inhibition
by 7.5 nM TMC207 was detected (Fig. 4.2B). As a further control, inhibition
by sodium azide (10 mM), an inhibitor known to act in a proton motive force
dependent manner [Syroeshkin et al., 1995, Bald et al., 1998], increased from
< 5% in the absence of the uncoupler to > 50% in the presence of the high-
est uncoupler concentration (data not shown). Thus, the proton motive force
does not significantly influence the target’s ability for binding of TMC207, nei-
ther by inducing conformational changes in ATP synthase, nor by outcompeting
TMC207 from its binding site. These data strongly suggest that TMC207 does
not directly compete with protons for a common binding site.
4.3.2 TMC207 inhibits ATP synthesis at low and neutral
pH values
Next, we investigated if (de-) protonation of TMC207 or of mycobacterial ATP
synthase affects drug/target interaction. The membrane vesicles from M. smeg-
matis were capable of detectable ATP synthesis activity over the whole pH range
investigated (pH 5.25-pH 7.5). As shown in Fig. 4.3, the external pH did not
significantly influence the inhibitory action of TMC207 between pH 5.25− 7.5,
with IC50 values determined to 5.0 − 7.5 nM for all pH values tested. Thus,
neither (de-) protonation of TMC207 nor (de-) protonation of the target in the
pH range investigated significantly changed the drug’s ability to interact with
its target. The dimethyl-amino group of TMC207 can take up a proton, which
can be observed by a peak shift from 1.87 ppm to 2.18 ppm in the 1H NMR
spectrum (data not shown). A pKa value of 9.0 − 10.0 in aqueous solution is
predicted, although this value may be lower in a hydrophobic membrane envi-
ronment. Most of the inhibitor molecules will be protonated at neutral or acidic
pH and the concentration of protonated TMC207 will not change significantly
during a titration between pH 5.25 and 7.5 (< 1.1-fold increase according to the
Henderson-Hasselbalch equation, assuming a pKa of 9.5). The concentration of
unprotonated TMC207 is expected to decrease strongly from pH 7.5 to pH 5.25
(> 100-fold according to the Henderson-Hasselbalch equation). The lack of pH
dependency observed in our experiments thus suggests that the protonated form
of TMC207 is the active drug entity.
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Figure 4.3: Effect of TMC207 on mycobacterial ATP synthesis at low pH. ATP synthe-
sis in the presence of TMC207 and varying external pH values was measured for Mycobac-
terium smegmatis inverted membrane vesicles (1 mg mL−1). Samples were incubated at 37 ◦C
for 1 h in the presence of an ADP-regenerating system, and produced ATP was quantified
spectrophotometrically by monitoring oxidation of glucose-6-phosphate with NADP+. As a
control, 100µM DCCD was added.
4.3.3 Electrostatic interactions are important for binding
of TMC207
Docking studies predict that electrostatic interactions play an important role in
binding of TMC207 to ATP synthase [de Jonge et al., 2007,Upadhayaya et al.,
2009].
To test this prediction, we determined the effect of buffer ionic strength
on TMC207 action. ATP synthesis by M. smegmatis membrane vesicles was
susceptible to TMC207 at all ionic strengths conditions investigated (0 mM,
300 mM and 600 mM NaCl) (Fig. 4.4A). However, sensitivity was clearly lower
at high ionic strength, with IC50 values increasing from 3.9 nM at 50 mM NaCl,
5.0 nM (300 mM NaCl) to 12.9 nM (600 mM NaCl).
To support this finding, we used Surface Plasmon Resonance Sensing to
characterize the interaction between TMC207 and purified ATP synthase sub-
unit c. For these experiments we used an analog of TMC207, which carries an
amino group instead of a bromine group [Koul et al., 2007] linked onto the chip.
Subsequently, we tested the influence of various salt concentrations (50 − 300
mM) in the subunit c sample and in the running buffer on drug/target interac-
48 Chapter 4. Probing the interaction . . .
0.
00
1
0.
00
25
0.
00
5
0.
02
5
0.
1 1
D
C
C
D
0
25
50
75
100
0 mM NaCl
300 mM NaCl
600 mM NaCl
TMC207 (µM)
R
e
la
ti
v
e
 i
n
h
ib
it
io
n
 (
%
)
A B
0 25 50 75 100
0
25
50
75
50 mM NaCl
150 mM NaCl
300 mM NaCl
Time (sec)
R
e
s
p
o
n
s
e
 (
R
U
)
Figure 4.4: Electrostatic interactions are important for binding of TMC207. (A) ATP syn-
thesis in the presence of TMC207 and increasing sodium chloride concentrations was measured
for inverted membrane vesicles of Mycobacterium smegmatis (1 mg mL−1). Samples were in-
cubated at 37 ◦C for 1 h in the presence of an ADP-regenerating system, and produced ATP
was quantified spectrophotometrically by monitoring oxidation of glucose-6-phosphate with
NADP+. As a control, 100µM DCCD was added. (B) BIAcore binding studies. Purified sub-
unit c from wild-type Mycobacterium tuberculosis was injected onto a chip with immobilized
amine analog of TMC207 in the presence of 50, 150 and 300 mM NaCl at 37 ◦C.
tion. Increasing concentration of shielding ions significantly decreased binding
affinity (Fig. 4.4B). The equilibrium dissociation constants (KD) in the presence
of 50 mM, 150 mM and 300 mM NaCl were determined to 1.5µM, 4.2µM and
19.7µM, respectively. The deviation between KD values and IC50 values may
be explained by subunit a contributing to the TMC207 binding site as well [de
Jonge et al., 2007, Koul et al., 2007, Upadhayaya et al., 2009]. The stronger
ionic strength dependency observed in the BIAcore binding assays may be due
to full accessibility of both drug and target for the salt ions, whereas in the
membrane vesicle ATP synthesis assay the binding site of TMC207 supposedly
is less accessible for the salt ions.
Our results suggest that electrostatic forces are an important factor for bind-
ing of TMC207 to ATP synthase, more specifically to its subunit c.
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4.3.4 TMC207 binds to a distinct binding site in ATP
synthase
ATP synthase is a complex membrane protein and in particular its membrane
spanning regions may provide multiple binding sites for a predominantly hy-
drophobic molecule, such as TMC207. Therefore, we investigated if the inhibi-
tion of synthesis by TMC207 can be explained by binding of a single molecule
TMC207 per ATP synthase complex. As depicted in Fig. 4.5A, the dose-
dependent inhibition of the ATP synthesis by TMC207 could be fitted accu-
rately (R2 > 0.99) with a simple one-site saturation-binding curve. This indi-
cates that interaction of TMC207 with a distinct binding site in ATP synthase
is responsible for inhibition of ATP synthesis.
In order to corroborate this result, we also determined if binding of TMC207
to purified subunit c from M. tuberculosis or to the purified ATP synthase
holoenzyme from Bacillus PS3 is consistent with a one-site binding mechanism.
The Surface Plasmon Resonance studies showed that both M. tuberculosis sub-
unit c and Bacillus PS3 ATP synthase bound to the TMC207 amine-analog
immobilized on a BIAcore chip (Fig. 4.5B and C). In both cases the obtained
binding curves could be fitted well (R2 > 0.99) with a simple mono-exponential
model, indicating only one type of binding site (Fig. 4.5B and C). Taken to-
gether, our results suggest that TMC207 binds to a distinct drug-binding site,
most likely one molecule TMC207 is sufficient to block the target enzymes ac-
tivity.
4.3.5 Mechanism of TMC207/target interaction
Insight in the mode of binding of antibacterial drugs to their target proteins is
an important step in understanding the mechanism of drug action. Moreover,
new drug derivates may be designed based on knowledge of drug/target interac-
tion [Upadhayaya et al., 2009]. Previously, docking studies based on free energy
minimization predicted a binding niche for TMC207 in mycobacterial ATP syn-
thase [de Jonge et al., 2007,Upadhayaya et al., 2009]. This site is mainly made
up by subunit c, supplemented with residues from subunit a. More specifically,
TMC207 in an extended conformation [Gaurrand et al., 2006] has been pro-
posed to interact via its protonated basic amino group with the carboxyl group
of glutamate61 in subunit c [de Jonge et al., 2007,Upadhayaya et al., 2009].
Our results show that TMC207 binds to a single drug-binding site within
ATP synthase with electrostatic interactions playing an important role in drug
binding. Most likely, the protonated form of TMC207 is the active molecule.
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Figure 4.5: TMC207 binds to one defined binding site in ATP synthase. (A) The dose-
dependency of ATP synthesis inhibition by TMC207 in inverted membrane vesicles of My-
cobacterium smegmatis was fitted with a one-site binding hyperbola (y = 104.9x
6.3+x
, R2 > 0.99).
(B) Binding of purified ATP synthase subunit c from Mycobacterium tuberculosis to an
amine analog of TMC207 linked onto a BIAcore chip was fitted using mono-exponential bind-
ing models (Association = Req
(
1− e−53737x
)
and Dissociation = 165.654e−0.002295(x−45),
R2 > 0.99), and (C) Binding of purified ATP synthase from Bacillus PS3 to an amine
analog of TMC207 linked onto a BIAcore chip was fitted using mono-exponential binding
models (Association = Req
(
1− e−153.7x
)
and Dissociation = 8575.97e−0.0001030(x−1187),
R2 > 0.99).
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These results are consistent with the model proposed by [de Jonge et al., 2007],
as the predicted interaction of the protonated amino group of TMC207 with
Glu61 predominantly is electrostatic in character and contributes significantly
to efficient drug binding. These electrostatic interactions are expected to be ac-
companied by hydrophobic and stacking interactions between aromatic rings of
TMC207 and aromatic side chains in subunit c [Upadhayaya et al., 2009], which
may explain why in our experiments even at high salt concentrations still signif-
icant binding was observed. The observed lack of competition between TMC207
and protons for a common binding site suggests that protonated TMC207 may
interfere with conformational changes in ATP synthase, e.g. block the rotary
motion of subunit c. This result is consistent with the hypothesis that TMC207
prevents rotation of subunit c by mimicking the function of arginine186 in sub-
unit a [de Jonge et al., 2007], a conserved basic residue in the proton transfer
chain [Valiyaveetil & Fillingame, 1997].
Taken together, our results are consistent with previous predictions based on
docking studies. TMC207, bound in a defined niche at the interface of subunits
c and subunit a, may interfere with proton transfer and subsequently block
conformational changes associated with ATP synthase activity.
4.3.6 TMC207 can be active in a broad range of physio-
logical microenvironments
Mycobacteria can persist in a mammalian host in “low energy” environments
due to exceptional metabolic flexibility [Berney & Cook, 2010], e.g. in poorly
aerated parts of the lung, within encapsulated lesions or within the endosome
system of host macrophages [Flynn & Chan, 2003]. Bacteria in these microenvi-
ronments are notoriously difficult to kill with antibacterials, such as isoniazid or
ethionamide [Gengenbacher et al., 2010,Gomez & McKinney, 2004]. Previously,
it was demonstrated that mycobacteria cultivated in vitro in low oxygen tension
model systems were efficiently killed by TMC207 [Koul et al., 2008,Rao et al.,
2008]. However, in addition to low oxygen tension, mycobacterial microenviron-
ments can display nutrient limitation, which may allow for only a low proton
motive force across the cytoplasmatic membrane [Huang et al., 2007]. More-
over, mammalian granuloma can be acidic due to active inflammation, with pH
values as low as 5.0 [Zhang & Mitchison, 2003]. The high affinity of TMC207 for
its target at both low proton motive force and low pH values may contribute to
the drug’s ability to render infected tissue culture-negative in mice faster than
current first- and second-line antibiotics [Andries et al., 2005, Ibrahim et al.,
2007,Lounis et al., 2006].
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4.4 Conclusion
Our results show that TMC207 binds to a distinct drug-binding site in its target
and we provide experimental support for a binding model previously proposed
based on docking studies [de Jonge et al., 2007]. The drug most likely interferes
with proton transfer and blocks conformational changes associated with proton
flow.
TMC207 efficiently interacts with its target independent of environmental
conditions such as the local pH and the proton motive force. These properties,
combined with the essentiality of the target, may explain how TMC207 can act
as a highly potent antibacterial drug.
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Abstract
Tuberculosis accounts for approximately 2 million deaths per year and an es-
timated one third of the world’s population is latently infected with Mycobac-
terium tuberculosis. Current tuberculosis treatment regimens involve > 6
months combination therapy with first-line antibiotics. This extended chemo-
therapy with concomitantly low patient compliance significantly contributes to
the emergence of multidrug- and extensively drug-resistant strains of M. tu-
berculosis. For effective control of tuberculosis, drugs with new mechanism
of action and interfering with novel target pathways new antimycobacterial
drugs are urgently needed. Diarylquinolines are a class of highly promising
new candidate-drugs for tuberculosis treatment, which specifically interact with
mycobacterial ATP synthase. Diarylquinoline lead compound TMC207 blocks
respiratory ATP production, leading to decreased cellular ATP levels and sub-
sequently bacterial killing after 3 − 4 days. Elucidation of the metabolic re-
sponse to antibiotic treatment can provide insight in mechanisms of bacterial
metabolic adaptation. Moreover, knowledge of metabolic remodeling can reveal
points of vulnerability in bacterial metabolism, which may be exploited for ef-
ficient design of drug co-administration. Mycobacterium bovis BCG responds
to treatment with the diarylquinolines lead compound TMC207 by downreg-
ulating DNA replication, nucleotide and protein synthesis. The mycobacteria
may slow down these biosynthesis pathways in order to save ATP and conserve
cellular energy charge. Concordantly, several proteins associated with the stress
response and protein refolding were upregulated, possibly indicating a shift from
de novo synthesis to re-usage and recycling of existing proteins. Components of
energy metabolism were upregulated, suggesting enhanced attempts to increase
cellular ATP production. The metabolic response determined here may allow
the mycobacteria to survive in the presence of the drug for several days and
may in part explain the delayed onset of bactericidal action by TMC207.
5.1 Introduction
Tuberculosis accounts for approximately 2 million deaths per year and an es-
timated one third of the world’s population is latently infected with Mycobac-
terium tuberculosis [Dye & Williams, 2010, Russel et al., 2010]. Current tu-
berculosis treatment regimens involve > 6 months combination therapy with
the first-line antibacterials isoniazid, rifampin, pyrazinamide, and ethambutol.
This extended chemotherapy with concomitantly low patient compliance signifi-
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cantly contributes to the emergence of multidrug- and extensively drug-resistant
strains of M. tuberculosis [Check, 2007,Dye, 2009]. For effective control of tu-
berculosis, thus new antimycobacterial drugs are urgently needed [Bald & Koul,
2010,Koul et al., 2011]. In particular, drugs with new mechanism of action and
interfering with novel target pathways are required.
Diarylquinolines are a class of highly promising new candidate-drugs for tu-
berculosis treatment, which specifically interact with mycobacterial ATP syn-
thase, leading to time-dependent depletion of cellular ATP levels [Koul et al.,
2007,Koul et al., 2008,Rao et al., 2008]. Transposon mutagenesis analysis has
suggested that ATP synthase is an essential enzyme for growth in M. tubercu-
losis [Sassetti et al., 2003] and for growth on fermentable and non-fermentable
carbon sources inMycobacterium smegmatis [Tran & Cook, 2005]. Diarylquino-
lines lead compound TMC207 is highly bactericidal on drug sensitive and drug
resistant M. tuberculosis [Andries et al., 2005, Diacon et al., 2009, Huitric et
al., 2007], and displayed surprising selectivity with only minimal effect on hu-
man mitochondria and minimal side effects for the human host [Andries et al.,
2005,Diacon et al., 2009,Haagsma et al., 2009]. In vivo, TMC207 showed de-
layed bacterial killing: whereas hardly any bactericidal activity was detectable
within the first 3 days of administration in treatment-na¨ıve patients with sputum
smear-positive pulmonary tuberculosis in a clinical phase IIa trial, significant
bacterial killing was observed after 4 days of treatment and onward [Rustomjee
et al., 2008]. The reason for this delay in bactericidal activity is unknown.
Bacteria can attempt to evade antibiotic action by a variety of mechanisms,
such as prevention of pro-drug activation, drug extrusion, modification of target
proteins or target pathway, as well as remodeling of bacterial metabolism [Walsh,
2000]. Elucidation of the metabolic response to antibiotic treatment can provide
insight in mechanisms of bacterial metabolic adaptation. Moreover, knowledge
of metabolic remodeling in presence of antibacterial drugs can reveal points
of vulnerability in bacterial metabolism, which may be exploited for efficient
design of drug co-administration.
In this report we use a proteomics approach to elucidate the metabolic re-
sponse to the diarylquinoline TMC207.
5.2 Materials and methods
5.2.1 Bacterial strains and growth conditions
Mycobacterium bovis BCG Copenhagen was kindly provided by B.J. Appelmelk,
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Department of Molecular Cell Biology & Immunology, VU University Medical
Center Amsterdam, The Netherlands. M. bovis BCG was grown in Middlebrook
7H9 broth (Difco) with 10% Middlebrook albumin-dextrose-catalase enrichment
(BBL) and 0.05% Tween-80 at 37 ◦C.
For the isotopically labeled internal standard, cells were grown on modified
Middlebrook 7H9 broth. 22 g L−1 D(+)-glucose monohydrate and 0.05% Triton
WR1339 (Tyloxapol, SigmaUltra) were additionally added with the internal
standard. Cells were harvested in the late exponential phase.
5.2.2 Cell lysis
Cell lysis was performed as described by [Fischer et al., 2006] with the modifica-
tions described below. Briefly, the bacteria were sedimented by centrifugation at
6, 000 g for 15 min and washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4, pH 7.4). The washed cells were resuspended in
disintegration buffer (PBS containing additional 20 mM MgCl2, 5 mM MnCl2,
200 units mL−1 DNase I (Invitrogen), protease inhibitors (complete, EDTA-free;
protease inhibitor cocktail tablets from Roche) at a concentration of 4 mL of
buffer per gram of wet cells. The cells were disrupted by three passages through
a pre-cooled French pressure cell at 20, 000 psi (Thermo Electron, 40K) with the
unbroken cells being subsequently sedimented twice by centrifugation at 6, 000 g
at 4 ◦C. The membranes were pelleted at 100, 000 g at 4 ◦C for 30 min and the
pellet of membranes was washed with PBS. After the second centrifugation step,
the membranes were resuspended in an appropriate volume of PBS.
5.2.3 Digestion conditions
Three biological replicates were analysed before and after TMC207 treatment
for each of the three distinct treatments (1 day, 2 days and 3 days TMC207
treatment). For the direct cytosolic analysis 100µg cytoplasmatic proteins were
pooled with an internal 15N-labeled standard in equal protein amounts and
incubated at 60 ◦C for 1 h to inactivate the protease inhibitors. For the digestion
4µg sequencing grade trypsin (Promega, Madison, USA) was added per 100µg
of proteins and the preparations were incubated at 60 ◦C over night. After
centrifugation at 100, 000 g for 30 min (4 ◦C), the supernatants, containing the
peptides, were finally desalted with Spec PT C18AR solid phase extraction
pipette tips (Varian, Lake Forest, CA, USA).
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5.2.4 One-dimensional nLC-ESI-MS/MS
Desalted samples were resuspended in 10µL buffer A (0.1% formic acid in wa-
ter) by sonication for 5 min and subjected to 1D-nLC-ESI-MS/MS using an
autosampler. An UPLC BEH C18 column (1.7µm, 75µm × 150 mm, Wa-
ters, Milford, MA, USA) and an UPLC Symmetry C18 trapping column (5µm,
180µm × 20 mm, Waters, Milford, MA, USA) for LC as well as a PicoTip
Emitter (SilicaTip, 30µm, New Objective, Woburn, MA, USA) were used in
combination with the nanoACQUITY gradient UPLC pump system (Waters,
Milford, MA, USA) coupled to a Thermo LTQ Orbitrap XL ion trap mass
spectrometer from Thermo Fisher Scientific Inc. (Waltham, MA, USA). For
each biological replicate two technical replicates were performed. 8µL of the
sample were loaded onto the column, equilibrated in 99% buffer A, using the
nanoAcquity autosampler. For elution of the peptides a linear gradient with
increasing concentration of buffer B (0.1% formic acid in acetonitrile) from 1%
to 40% within 165 min was applied, followed by a linear gradient from 40% to
99% acetonitrile concentration within 15 min (0− 5 min: 1% buffer B; 5− 10
min: 5% buffer B; 10− 175 min: 40% buffer B; 175− 200 min: 99% buffer B;
200−210 min: 1% buffer B) at a flow rate of 400 nL min−1 and a spray voltage
of 1.2− 1.5 kV. The LTQ Orbitrap was operated by instrument method files of
Xcalibur (Rev. 2.0.7). The linear ion trap and orbitrap were operated in paral-
lel, i.e. during a full MS scan on the orbitrap in the range of 300− 2000 m/z at
a resolution of 60, 000. MS/MS spectra of the four most intense precursors were
detected in the ion trap. The analytical column oven was set to 45 ◦C and the
heated desolvation capillary was set to 200 ◦C. The relative collision energy for
collision-induced dissociation was set to 35%. Dynamic exclusion was enabled
with a repeat count of 1 and a 30 seconds exclusion duration window. Singly
charged and more than triply charged ions were rejected from MS/MS.
5.2.5 Data analysis
All database searches were performed using SEQUEST algorithm, embedded in
Bioworks Browser TM (Rev. 3.3.1 SP1, Thermo Electron c© 1998-2007) with
a M. bovis BCG database containing 3953 sequences, which was available at
NCBI. Each raw file was searched against both, the database with 14N-label
and 15N-label. Furthermore, mass accuracy was set to 10 ppm and the oxida-
tion of methionine was admitted as a variable peptide modification. Protein
quantification was performed using the ProRata 1.0 algorithm [Pan et al., 2006]
to calculate peak areas of unlabeled 14N peptides and of metabolically labeled
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15N peptides. The relative quantification using the ProRata software was per-
formed as already reported with the following parameters: minimum ∆Cn was
set to 0.08, minimum XCorr was set to 2.5 (+2), 3.5 (+3), duplicate spectra
for each sequence were retained (−t 0) and at least two different peptides per
protein were required.
5.3 Results
5.3.1 Mycobacterial growth in presence of TMC207
In this study we used the slow-growing M. bovis BCG as a model system, which
shares > 99.9% DNA sequence identity with M. tuberculosis and strongly re-
semblesM. tuberculosis in terms of growth rate, energy metabolism and sensitiv-
ity to diarylquinolines [Huitric et al., 2007,Mattow et al., 2001]. To investigate
TMC207-induced changes in bacterial growth, M. bovis BCG was cultured in
liquid medium in the presence or absence of TMC207. In the absence of TMC207
cell density increased steadily, with an average OD600 of ∼ 0.4 after 4 days and
∼ 1.0 after 8 days (Fig. 5.1). In the presence of 125 nM TMC207 (1× MIC90),
added on day 4, the cell density further increased for 1−2 days and then leveled
off at OD values ∼ 0.6. As negative control, addition of DMSO, the solvent used
for TMC207, did not significantly influence mycobacterial growth (Fig. 1). Our
results using M. bovis BCG are consistent with the time-dependent activity of
TMC207 reported earlier for M. tuberculosis [Andries et al., 2005].
5.3.2 Overall changes in protein expression
To investigate TMC207-induced metabolic changes, M. bovis BCG protein ex-
pression was examined and quantified within a 3-day interval after adding the
compound. 72 proteins were found differentially regulated with a log2 regulation
factor > 0.3 or < −0.3 and p < 0.05 (Table 5.1). The number of significantly
regulated proteins increased from 12 (day 1) to 28 (day 2) and finally 38 (day
3).
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Figure 5.1: Growth curves for Mycobacterium bovis BCG. Bacteria were cultured for 8 days
in Middlebrook 7H9 broth (Difco) containing 10% Middlebrook albumin-dextrose-catalase
enrichment (BBL) and 0.05% Tween-80 with the following additions after 4 days: (△) 125
nM TMC207 (1 × MIC90), (⋄) 0.25% DMSO, (•) none . The results shown represent the
mean ± SD from three different experiments.
Table 5.1: Differentially expressed proteins in Mycobacterium bovis BCG during TMC207
treatment.
ID Protein Description log2 p-value
ratio
BCG 0289c HrpA Heat shock protein HrpA 4.2 0.001
5.1 0.002
BCG 1527 BCG 1527 Conserved hypothetical protein 3.4 0.005
BCG 3931 BCG 3931 Conserved hypothetical protein 2.8 0.044
BCG 0829 PurB Adenylosuccinate lyase 2.8 0.014
BCG 1693 ArgB Acetylglutamate kinase 2.7 0.009
BCG 0226c IlvD Dihydroxy-acid dehydratase 2.4 0.015
BCG 2696 BCG 2696 Conserved hypothetical protein 2.4 0.005
BCG 0507 Icl Isocitrate lyase icl 0.4 0.022
0.7 0.049
1.6 0.0001
BCG 1385 FadA4 Acetyl-CoA acetyltransferase fadA4 1.1 0.006
BCG 0282c FadE5 Acyl-CoA dehydrogenase fadE5 0.5 0.016
1.0 0.049
BCG 0751 RplC 50S ribosomal protein L3 1.0 0.006
BCG 3863c FadD32 Fatty-acid-CoA ligase fadD32 0.8 0.005
BCG 2962c Mas Putative mycocerosic acid synthase 0.8 0.038
BCG 3770 LeuA 2-isopropylmalate synthase 0.8 0.035
BCG 2295 BCG 2295 Probable dehydrogenase 0.8 0.029
BCG 2132c BCG 2132c Probable ATPase 0.8 0.012
BCG 0502 Lpd Dihydrolipoamide dehydrogenase 0.7 0.023
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BCG 0390 GrpE Probable GrpE protein 0.7 0.049
0.6 0.013
BCG 0389 DnaK Probable chaperone protein DnaK 0.3 0.014
0.6 0.0001
BCG 0422c ClpB Putative endopeptidase ATP binding 0.6 0.015
protein (chain b) clpB 0.3 0.049
BCG 3185c BCG 3185c Possible dioxygenase 0.6 0.004
BCG 0077c Ino1 Myo-inositol-1-phosphate synthase INO1 0.6 0.028
BCG 2724 IdeR Iron-dependent repressor and activator ideR 0.6 0.014
BCG 1509c Tal Transaldolase 0.6 0.024
BCG 1498 Pgk Phosphoglycerate kinase 0.5 0.021
BCG 0097c Icd2 Putative isocitrate dehydrogenase 0.5 0.041
BCG 3277c SahH S-adenosyl-L-homocysteine hydrolase 0.5 0.029
BCG 1872c GlcB Malate synthase G 0.4 0.027
BCG 0281 FadA2 Acetyl-CoA acetyltransferase fadA2 0.4 0.005
BCG 2993 BCG 2993 Probable oxidoreductase 0.4 0.029
BCG 3017c SerA1 D-3-phosphoglycerate dehydrogenase 0.4 0.049
BCG 2128c BCG 2128c Conserved hypothetical protein −0.3 0.039
0.4 0.033
BCG 1006 SucD Succinyl-CoA synthetase subunit alpha 0.3 0.034
BCG 1537c Acn Aconitate hydratase 0.3 0.005
BCG 0912 FadB Fatty oxidation protein fadB 0.3 0.045
BCG 1947c KatG Catalase-peroxidase-peroxynitritase T katG 0.3 0.033
BCG 3069 AdhC NADP-dependent alcohol dehydrogenase adhC −0.3 0.036
BCG 1194c MetE 5-methyltetrahydropteroyltriglutamate- −0.3 0.048
homocysteine S-methyltransferase
BCG 3522c RpoA DNA-directed RNA polymerase subunit alpha −0.3 0.042
BCG 2487 PepN Putative aminopeptidase N pepN −0.4 0.016
−0.3 0.01
BCG 1449 MihF Putative integration host factor mihF −0.4 0.012
BCG 3776c BCG 3776c Conserved hypothetical protein −0.4 0.049
BCG 3052c FixA Probable electron transfer flavoprotein −0.4 0.048
(beta-subunit) fixA
BCG 0936c SerC Phosphoserine aminotransferase −0.4 0.014
BCG 2545c FAS I Putative fatty acid synthase I −0.4 0.040
BCG 0717 RpoC DNA-directed RNA polymerase beta −0.4 0.014
BCG 0701 RplL 50S ribosomal protein L7/L12 −0.5 0.046
BCG 1668 RpsA 30S ribosomal protein S1 −0.5 0.042
BCG 0768 RpsH Probable 30S ribosomal protein S8 −0.5 0.043
BCG 2482c Tig Trigger factor −0.5 0.019
BCG 2261 AcpM Meromycolate extension acyl carrier −0.5 0.016
protein acpM
BCG 1896 Apa Alanine and proline rich secreted protein −0.5 0.028
−0.5 0.017
BCG 3935c BCG 3935c Conserved hypothetical protein −0.5 0.033
BCG 0002 DnaN DNA polymerase III subunit beta 0.3 0.010
−0.6 0.036
BCG 1650 TrpB Tryptophan synthase subunit beta −0.6 0.05
BCG 2315c HtpG Probable chaperone protein htpG −0.7 0.008
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−0.3 0.016
BCG 1154 DesA2 Possible acyl-[acyl-carrier protein] −0.7 0.044
desaturase desA2
BCG 1579c Pks5 Putative polyketide synthase pks5 −0.9 0.011
BCG 3573c IlvX Acetohydroxyacid synthase ilvX −0.9 0.012
BCG 3850 BCG 3850 Conserved hypothetical protein −0.9 0.009
BCG 3768c Asd Aspartate-semialdehyde dehydrogenase −2.1 0.0004
BCG 2448 AhpD Alkyl hydroperoxide reductase D protein ahpD −2.1 0.037
BCG 1879c GuaB1 Inosine 5-monophosphate dehydrogenase −2.2 0.0001
BCG 0532 RegX3 Two component sensory transduction −2.3 0.003
protein regX3
BCG 2464c Rne Putative ribonuclease E −2.4 0.010
BCG 3747 BCG 3747 Conserved hypothetical protein −2.5 0.01
BCG 0229 BCG 0229 Conserved hypothetical protein −2.6 0.017
BCG 2865c ProS Prolyl-tRNA synthetase −2.6 0.009
BCG 2969c FadD22 Fatty-acid-CoA ligase fadD22 −2.6 0.009
BCG 0253 BCG 0253 Conserved hypothetical protein −2.8 0.046
BCG 1470 RibG Putative bifunctional riboflavin biosynthesis −2.9 0.041
protein RIBG
BCG 2653c BCG 2653c Conserved hypothetical protein −3.6 0.003
5.3.3 Differentially regulated Metabolic Pathways
General stress response
Response to stress is crucial for the bacterial survival and bacteria have de-
veloped a number of mechanisms to evade or cope with stress factors, such as
reactive nitrogen and reactive oxygen species, low nutrient conditions, or expo-
sure to radiation.
In cultures containing TMC207 several proteins typically associated with
stress responses were found significantly upregulated (Fig. 5.2). The heat shock
protein HrpA suppresses aggregation of proteins by associating with ribosomes
and cell membrane [Tabira et al., 2000]. ATP binding protein (chain b) clpB
is involved in re-solubilization of aggregated proteins [Doyle & Wickner, 2009].
Chaperone protein DnaK has functions in refolding of misfolded proteins and
folding of newly synthesized proteinsa and endopeptidase GrpE functions to-
gether with DnaJ as a co-chaperone for DnaK [Bukau & Horwich, 1998]. ClpB
and DnaK appear to act synergistically wherein DnaK may assist ClpB dur-
ing the initials stages of protein unfolding by presenting unstructured regions
of the polypeptide to ClpB, by modulating the ATPase activity of ClpB, or
by helping refold proteins following their extrusion from ClpB [Doyle & Wick-
ner, 2009]. During the course of treatment heat shock protein HtpG, with a
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Figure 5.2: TMC207-induced expression changes of proteins involved in general stress re-
sponse.
poorly understood function, becomes less downregulated. HtpG is incapable
of folding newly synthesized proteins alone, but is essential for the complete
refolding process in Escherichia coli. HtpG may function as a holdase immedi-
ately following polypeptide extrusion from ClpB by maintaining a protein in a
conformation suitable for DnaK-dependent refolding [Thomas & Baneyx, 2000].
These findings indicate that mycobacteria under TMC207-induced stress may
opt to preserve protein intactness or refold proteins instead of de novo protein
synthesis.
M. tuberculosis has evolved multiple ways to detoxify reactive nitrogen and
reactive oxygen species. Strong downregulation was observed for alkyl hydroper-
oxide reductase D protein (AhpD), whereas catalase-peroxidase KatG, which
detoxifies superoxide and peroxynitrite, was mildly upregulated. AhpD acts
by reducing the alkyl hydroperoxide reductase (AhpC), a peroxidase and per-
oxynitrate reductase involved in antioxidant defense mechanisms [Bryk et al.,
2000,Bryk et al., 2002]. Apparently, TMC207 does not elicit a significant ox-
idative stress in the mycobacterial cell.
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Figure 5.3: TMC207-induced expression changes of proteins involved in DNA replication
and nucleotide synthesis.
DNA replication and nucleotide synthesis
Several proteins involved in nucleotide or DNA metabolism were found signif-
icantly downregulated. Inosin 5-monophosphate dehydrogenase (GuaB1) and
bifunctional riboflavin biosynthesis protein RIBG, both enzymes involved in
nucleotide synthesis, were strongly downregulated (Fig. 5.3). For DNA Poly-
merase III (DnaN), a key enzyme in DNA replication, regulation was more
complex, with moderate increase of expression after one day and a stronger
decraese at day 2. This observed downregulation of DNA biosynthetic path-
ways most likely is a way to conserve the cells energy and resources when ATP
synthesis is blocked by TMC207.
Protein biosynthesis
Protein synthesis is a major energy sink in mycobacterial metabolism [Cox &
Cook, 2007]. Protein biosynthesis involves both production of mRNA and ribo-
somal synthesis of proteins. In TMC207-treated bacteria downregulation was
observed for subunits alpha and beta of DNA-directed RNA polymerase (Rpo),
a key enzyme in transcription (Fig. 4). Moreover, ribosomal components, such
as the 50S ribosomal protein L7/12 (RplL), 30S ribosomal protein S1 (RpsA)
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Figure 5.4: TMC207-induced expression changes of proteins involved in protein biosynthesis.
and S8 (RpsH) were significantly downregulated. Downregulation of the prolyl-
tRNA synthetase (ProS) indicates that less energy is spent for loading of amino
acids to tRNAs. RpIL, RpsA, RpsH and ProS are implicated in translation of
mRNA to protein. Decreased Rne expression probably is a means to prevent
degradation of mRNA (Fig. 4), the cell may save energy by extending mRNA
life time. When newly synthesized polypeptides emerge from the ribosomal
exit tunnel the ribosome-associated trigger factor is the first chaperone they en-
counter [Baram et al., 2005,Ferbitz et al., 2004,Kramer et al., 2002,Schlu¨nzen et
al., 2005]. The downregulation of protein biosynthesis in response to antibiotic
treatment is most likely a way to conserve the cell’s energy and resources.
Energy and intermediary metabolism
Bacteria can generate ATP either by substrate level phosphorylation of fer-
mentable carbon sources or by oxidative phosphorylation [Cox & Cook, 2007].
Whereas several other bacteria can provide sufficient energy for growth by sub-
strate level phosphorylation and increased glycolytic flux, ATP synthase was
shown to be essential for growth on both fermentable and non-fermentable car-
bon sources inM. smegmatis [Tran & Cook, 2005]. We investigated if blocking of
ATP synthase activity leads to shifts in cellular energy metabolism. In glycoly-
sis, phosphoglycerate kinase (Pgk) was found upregulated (Fig. 5.5). Pgk catal-
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Figure 5.5: TMC207-induced expression changes involved in energy and intermediary
metabolism.
yses one of the ATP-forming steps of glycolysis, transferring a phosphate group
from 1,3-biphosphoglycerate to ADP. Glycolysis is linked to the pentose phos-
phate pathway by transaldolase and transketolase, which convert 5-carbon sugar
phosphates of the pentose phosphate pathway, suitable for nucleotide synthesis,
into six-carbon units (fructose-6-phosphate) or 3-carbon units (glyceraldehyde
3-phosphate) that can enter glycolysis for ATP synthesis. Transaldolase (Tal)
was mildly upregulated (Fig. 5.5), possibly reflecting decreased cellular require-
ments for nucleotide components and increased demand for ATP.
Under aerobic conditions, pyruvate is oxidatively decarboxylated by pyru-
vate dehydrogenase to form acetyl CoA, which enters the tricarboxylic acid
(TCA) cycle. Dihydrolipoamide dehydrogenase (Lpd), one of the enzymes of
the pyruvate dehydrogenase complex was upregulated (Fig. 5.5), possible in-
dicating higher flux through this enzyme complex. This view is supported by
downregulation of acetohydroxyacid synthase (IlvX) (Fig. 5.5), which catalyzes
a competing reaction, the conversion of pyruvate to 2-acetolactate and CO2.
Several proteins of the TCA cycle were upregulated upon TMC207 exposure:
aconitase (Acn), isocitrate dehydrogenase (Icd2) and succinate dehydrogenase
(SucD) (Fig. 5.5). Moreover, pronounced upregulation of adenylosuccinate
lyase (PurB) (Fig. 5.5), which converts adenylosuccinate to AMP and fumarate
[Arago´n & Lowenstein, 1980,Tornheim & Lowenstein, 1975,Young et al., 1996],
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may increase levels of this TCA cycle intermediate. The TCA cycle may also
partly operate in reverse, e.g. succinate dehydrogenase potentially may act as
fumarate reductase, thus constituting an electron sink for redox balance.
These observed metabolic changes may indicate that the mycobacteria at-
tempt to increase substrate-level ATP production and/or to increase pressure
on the respiratory chain by enhanced production of reducing equivalents.
Fatty acids present an alternative source of energy widely used by mycobac-
teria. β-oxidation converts fatty acids into acetyl CoA, which can be fed in
the TCA cycle, yielding NADH/FADH2 as substrates for the respiratory chain.
Several components of fatty acid β-oxidation (FadB, FadE5, FadA2 and FadA4)
were upregulated during exposure to TMC207 (Fig. 5.5). Mycobacteria may
respond to blockage of respiratory ATP production by mobilization of cellular
energy storage systems.
Utilization of lipids as carbon source requires the carbon-conserving glyoxy-
late shunt. Isocitrate lyase (Icl), which catalyzes conversion of isocitrate to suc-
cinate and glyoxylate, the first reaction of this pathway branching from the TCA
cycle, was significantly upregulated. Regulation of malate synthase (GlcB), cat-
alyzing the second step of the glyoxylate shunt, the condensation of glyoxylate
with acetyl CoA to malate, was clearly less pronounced (Fig. 5.5). These data
may indicate a switch in metabolism to utilize lipids as carbon source. However,
alternatively, the higher demand for isocitrate lyase may be due to the role of
this enzyme in the methylcitrate cycle, metabolizing odd-chain fatty acids. In-
creased β-oxidation may yield high concentrations of propionyl-CoA, which can
enter the methylcitrate cycle [Upton & McKinney, 2007]).
Lipid biosynthesis
Mycobacteria have an unusual cell wall in which mycolic acids, a special type
of very long chain lipids, play a critical role in its structure and function. Lipid
biosynthesis in mycobacteria is a highly complex system, involving both type I
and type II fatty acid synthase enzymes, and accordingly mycobacteria employ
a broad array of enzymes for this task.
Downregulation was observed for the single multifunctional FAS I, which
carries out de novo biosynthesis of long chain fatty acyl-CoAs from acetyl-CoA
(Fig. 5.6). The multiple component synthase FAS II then elongates C16 acyl-
CoA to produce very long chain meromycolates. Acyl carrier protein M (AcpM),
a central component of the FAS II multi-enzyme complex, was shown to be less
expressed in presence of TMC207 (Fig. 5.6). Moreover, downregulation was
detected for fatty-acid-CoA ligase fadD22, involved in the biosynthesis of the
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Figure 5.6: TMC207-induced expression of proteins involved in lipid metabolism.
cell envelope component phenolic glycol lipids (PG) [Sime´one et al., 2010], and
for the aerobic desaturase desA2 (Fig. 5.6). This differential expression may
indicate a general decrease in fatty acid biosynthesis activity.
However, we observed upregulation for FadD32, an enzyme involved in the
final step of mycolic acid synthesis, condensation of a meromycolate chains
with long chain Acyl-CoA primers generated by FAS I [Trivedi et al., 2004].
The type II polyketide mycocerosic acid synthase (Mas), which synthesizes the
mycocerosic acid units for PGLs [Dubey et al., 2002,Mathur & Kolattukudy,
1992, Rainwater & Kolattukudy, 1985] was upregulated (Fig. 5.6). The type
II polyketide Pks 5 on the other hand, which is highly similar to Mas, was
downregulated.
Taken together, the changes in fatty acid biosynthesis in response to TMC207
treatment are complex. Although key components of Fas I and FASII are down-
regulated, we cannot exclude that several reactions of lipid biosynthesis are
accelerated in TMC207 treated cells.
Conserved hypothetical proteins
More than 25% of the M. tuberculosis proteome accounts for conserved hypo-
thetical proteins of unknown function. Several conserved hypothetical proteins
were differentially up- or downregulated, in particular BCG 0229, BCG 0253,
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Figure 5.7: TMC207-iinduced expression changes of conserved hypothetical proteins.
BCG 1527, BCG 2653c, BCG 2696, BCG 3747, BCG 3931 and BCG 3935c
displayed exceptionally high regulation factors (Fig. 5.7). An ortholog of
BCG 2653c, Rv2626c, is present in M. tuberculosis and is thought to have a
function in the dormancy regulon, a set of 48 genes crucial for survival under
non-replicating persistent conditions. It is likely that the conserved hypotheti-
cal proteins have important functions related to cellular (ATP) homeostasis and
definitely require further studies to define their roles in mycobacterial (energy)
metabolism.
5.4 Discussion
Taken together, we found that M. bovis BCG responds to TMC207 treatment
by downregulation of DNA replication, nucleotide and protein synthesis. The
mycobacteria may slow down these biosynthesis pathways in order to save ATP
and conserve cellular energy charge. Concordantly, proteins associated with
stress response and protein refolding were upregulated, indicating a shift from
de novo synthesis to re-usage and recycling of existing proteins. Components of
energy metabolism were upregulated, suggesting enhanced attempts to increase
cellular ATP production. The metabolic response determined here may allow
the mycobacteria to survive in the presence of the drug for several days and may
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in part explain the delayed onset of bactericidal action observed for TMC207
[Rustomjee et al., 2008].
Protein biosynthesis has been found downregulated in response to treatment
with other antibacterials as well, such as isoniazid and ethambutol [Wang &
Marcotte, 2008]. These drugs inhibit mycolic acid biosynthesis by targeting
enoyl-ACP reductase InhA of the FAS II system [Vilche`ze et al., 2006] and
arabinosyl transferase (EmbABC) [Takayama & Kilburn, 1989], repectively.
However, in contrast to TMC207, both isoniazid and ethambutol caused
pronounced upregulation of mycolic acid biosynthesis, in particular components
of the FAS II system [Hughes et al., 2006, Jia et al., 2005,Wang & Marcotte,
2008]. This response most is likely as a consequence of a regulatory feedback
mechanism to to compensate for the inhibitory effect of these drugs [Wang
& Marcotte, 2008]. Moreover, in contrast to TMC207, isoniazid significantly
induced the alkyl hydroperoxidase system [Wang & Marcotte, 2008].
Pyrazinamide is a first line antibiotic that acts on energy metabolism [Zhang
et al., 2003]. To our knowledge there are no studies available on the metabolic
response to pyrazinamide, it would be interesting to investigate if TMC207
and pyrazinamide, with a similar mechanism of action, share a related tran-
scriptomic/proteomic signature. Treatment with 5-Cl-pyrazinamide resulted
in a downregulation of protein biosynthesis and upregulation of TCA cycle
components [Wang & Marcotte, 2008], similar to the response observed here
for TMC207. However, there are indications that the mechanism of action
of 5-Cl-pyrazinamide and pyrazinamide may not be identical [Boshoff et al.,
2002,Zimhony et al., 2000].
Downregulation of protein and mycolic acid biosynthesis has also been ob-
served during shift to slow growth rate [Beste et al., 2007], nutrient starva-
tion [Betts et al., 2002], an oxygen depleted dormancy model [Voskuil et al.,
2004] and environmental acidification [Fisher et al., 2002]. However, these stress
situations also induced downregulation of components of the TCA cycle [Beste
et al., 2007,Betts et al., 2002], glyoxylate shunt [Beste et al., 2007,Betts et al.,
2002] and alkyl hydroperoxidase system [Fisher et al., 2002], in contrast to the
response to TMC207 treatment determined here.
In a mouse model of tuberculosis infection components of β-oxidation and
the glyoxylate/methylcitrate pathway were found upregulated [Shi et al., 2010].
In contrast to what is observed in this mouse model, TMC207 did not induce
downregulation of TCA cycle components [Shi et al., 2010].
Phagosomal uptake resulted in induction of the general stress response [Ro-
hde et al., 2007], the glyoxylate shunt or methylcitrate cycle (isocitrate lyase)
[Dubnau et al., 2002,Graham & Clark-Curtiss, 1999,Rohde et al., 2007,Schnap-
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pinger et al., 2003], and the β-oxidation pathway [Rohde et al., 2007, Schnap-
pinger et al., 2003], similar to the response observed here for TMC207. In
conclusion, stress by TMC207 largely seems to mimic phagosomal uptake.
Insight in the metabolic response to antibacterials may reveal points of phys-
iological vulnerability. Upregulation of isocitrate lyase, with either a function
in glyoxylate shunt or in the methylcitrate cycle, suggests that the significance
of this enzyme is enhanced in the presence of TMC207. Icl has previously been
validated as drug target, in particular for dormant or latent mycobacteria, and
small molecule inhibitors for this enzyme are known [Mun˜oz-El´ıas & McKin-
ney, 2005] . It might be promising to test co-administration of Icl inhibitors
with TMC207, which may act synergistically. Similarly, inhibitors of proteins
involved in the cellular stress response, such as heat shock protein HrpA and
chaperone protein DnaK, or compounds interfering with argininosuccinate lyase
function may be tested for synergy with TMC207.
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Abstract
Drug-resistant strains of Mycobacterium tuberculosis, the causative agent of
tuberculosis, pose a serious health challenge, urging development of new an-
tibacterial drugs. Mycobacterial ATP synthase has recently been validated as
target of the diarylquinolines, a new class of candidate drugs against tubercu-
losis. Here we report isolation of ATP synthase from the slow growing model
strain Mycobacterium bovis BCG. The isolated detergent-solubilised enzyme
displays low ATP hydrolysis activity and is sensitive to N,N ′-dicyclohexyl-
carbodiimide. Availability of isolated ATP synthase may help to investigate
interaction between diarylquinolines and ATP synthase. Moreover, the isolated
enzyme may be used to shed light on the unusual subunit composition of my-
cobacterial ATP synthase as suggested based on genomic data.
6.1 Introduction
Tuberculosis is an airborne infection caused by Mycobacterium tuberculosis. It
is estimated that one third of the world’s population is latently infected with
M. tuberculosis, more than 10 million new cases and nearly 2 million deaths
are reported annually [Dye & Williams, 2010,Russel et al., 2010]. Resistance of
mycobacterial strains to currently used antibacterials urgently calls for develop-
ment of new antibiotics with mechanism of action different from presently used
drugs [Check, 2007,Dye, 2009].
Energy metabolism has emerged as a new target-pathway for development of
new antimycobacterial drugs [Bald & Koul, 2010,Zhang et al., 2003]. Substrate-
level phosphorylation of fermentable carbon sources can be the sole energy
source in many bacteria, such as Escherichia coli and Bacillus subtilis [Friedl et
al., 1983, Santana et al., 1994]. However, in mycobacteria fermentation appar-
ently cannot provide sufficient energy for growth [Tran & Cook, 2005], leaving
ATP synthase with the role to provide the bulk of cellular ATP. In this way,
mycobacterial ATP synthase has attracted interest as target of a new class of an-
tibacterial drugs, the diarylquinolines [Andries et al., 2005,Koul et al., 2007,Bald
& Koul, 2010]. Diarylquinolines are strongly bactericidal on drug-resistant M.
tuberculosis, the lead compound TMC207 considerably improved standard reg-
imen in phase IIb clinical trials [Lounis et al., 2006, Diacon et al., 2009]. Di-
arylquinolines bind to mycobacterial ATP synthase with very high affinity (IC50
∼ 5 nM) [Koul et al., 2007] and remarkable selectivity (SI ∼ 20, 000 as com-
pared with human ATP synthase) [Haagsma et al., 2009]. The molecular basis
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for these surprising properties are not well understood, in part due to lack of an
over-expression or purification protocol for ATP synthase from M. tuberculosis
or related slow growing mycobacteria.
ATP synthase can use the energy of protons flowing along a transmembrane
electrochemical potential gradient for synthesis of ATP (for review see [Boyer,
1997,Junge et al., 1997]. The enzyme consists of a membrane-embedded portion
F0, responsible for proton flow across the membrane, with the subunit composi-
tion a1b2c10−15, and a soluble portion F1, which houses the nucleotide binding
sites and is composed of subunits a3β3γδε.
Although in some bacteria, ATP synthase can invert its function to pump
protons across the membrane for maintenance of the proton motive force (PMF),
in mycobacteria the main function of ATP synthase appears to be the produc-
tion of ATP [Haagsma et al., 2010]. Mycobacteria can survive in environments
with low nutrient availability and low pH values [Zhang et al., 2003], conse-
quently mycobacterial ATP synthase may display special adaptations to cope
with these challenging environmental conditions. In order to understand func-
tion and properties of mycobacterial ATP synthase, availability of the enzyme
in detergent-solubilised and isolated state is of importance.
In this study, a procedure for detergent solubilisation and isolation of the
ATP synthase from M. bovis BCG, a non-pathogenic mycobacterial model
strain, is described.
6.2 Materials and methods
6.2.1 Bacterial strains and growth conditions
Mycobacterium bovis BCG Copenhagen was kindly provided by B.J. Appelmelk,
Department of Molecular Cell Biology & Immunology, VU University Medical
Center Amsterdam, The Netherlands. Replicating cultures of M. bovis BCG
was grown in Middlebrook 7H9 broth (Difco) with 10% Middlebrook albumin
dextrose catalase enrichment (BBL) and 0.05% Tween-80 at 37 ◦C to the late
exponential phase.
6.2.2 Preparation of inverted membrane vesicles
Inverted membrane vesicles (IMVs) of M. bovis BCG were prepared as de-
scribed previously [Haagsma et al., 2010] with the modifications described be-
low. Briefly, cells were pelleted by centrifugation at 6, 000 g for 20 min and
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washed once with Phosphate-buffered saline (PBS, pH 7.4). Five grams of cells
(wet weight) were resuspended in 10 mL of 10 mM HEPES-KOH (pH 7.5), 5
mM MgCl2 and 10% glycerol including protease inhibitors (complete, EDTA
free; protease inhibitor cocktail tablets from Roche). Lysozyme (10 mg mL−1),
1500 units of deoxyribonuclease I (Invitrogen) and 12 mM MgCl2 were added
and cells were incubated with stirring at 37 ◦C for 1 h. The cells were broken by
three passages through a precooled French pressure cell at 20, 000 psi (Thermo
Electron, 40K). The lysate was centrifuged at 6, 000 g and 4 ◦C for 20 min to
remove unbroken cells. Two additional centrifugation steps at 6, 000 g and 4 ◦C
for 20 min were carried out to remove additional cell wall components. The su-
pernatant was centrifuged at 370, 000 g and 4 ◦C for 1 h and the pellet of IMVs
was resuspended in an appropriate volume of 10 mM HEPES-KOH (pH 7.5), 5
mM MgCl2 and 10% glycerol.
The intactness of ATP synthase in all preparations of the inverted mem-
brane vesicles were routinely analyzed by performing an ATP synthesis assay
as described by [Haagsma et al., 2010].
6.2.3 Membrane protein extraction and purification by
anion-exchange and size-exclusion chromatography
To extract the proteins from the cytoplasmatic membrane, inverted membrane
vesicles obtained from 3 grams ofM. bovis BCG were homogenized in 3 mL of 10
mM HEPES-KOH (pH 7.5), 5 mM MgCl2, 10% glycerol and 1.2% n-Dodecyl-
β-D-Maltopyranoside (DDM) (Affymetrix) including protease inhibitors (com-
plete, EDTA free; protease inhibitor cocktail tablets from Roche). After 1 h
of incubation at 4 ◦C with constant stirring, the homogenization mixture was
diluted 12-fold to 0.1% DDM with 10 mM HEPES-KOH (pH 7.5), 5 mM MgCl2
and 10% glycerol, followed by ultracentrifugation at 100, 000 g for 20 min to
remove nonsolubilized material.
The solubilized material was applied to a Resource Q column (1 mL, GE
Healthcare) equilibrated with 10 mM HEPES-KOH (pH 7.0), 50 mM NaCl, 2
mM MgCl2 and 0.03% DDM at a flow-rate of 0.8 mL min−1. Proteins were
eluted with a linear NaCl gradient (50 mM - 1 M) in 30 min. The fractions eluted
at 295 − 418 mM NaCl were combined and precipitated with 70% ammonium
sulphate. The pellet was resuspended in 600µL of 10 mM HEPES-KOH (pH
7.0), 50 mM NaCl, 2 mM MgCl2 and 0.03% DDM and applied to a Superdex
200 10/300 GL gel filtration column equilibrated with 10 mM HEPES-KOH
(pH 7.0), 50 mM NaCl, 2 mM MgCl2 and 0.03% DDM at a flow-rate of 0.5
mL min−1. Eluted proteins were concentrated by TCA-precipitation. Proteins
6.3. Results and discussion 85
were resuspended in sample buffer and resolved on sodium dodecyl sulphate
(SDS)-polyacrylamide gel (PAGE) and polypeptides were visualized by staining
with Coomassie brilliant blue.
6.2.4 Mass spectrometry
Selected protein bands from the Coomassie brilliant blue-stained gel were ex-
cised, in-gel trypsinized and analysed by mass spectrometry on an ABI 5700
MALDI TOF/TOF instrument according to [Sauri et al., 2009].
6.3 Results and discussion
As no over-expression system is available for mycobacterial ATP synthase we
here present an experimental procedure for isolation of mycobacterial ATP syn-
thase by detergent extraction and column chromatography. As model bacterium
we chose M. bovis BCG, a non-pathogenic strain, which strongly resembles M.
tuberculosis in terms of growth rate and sensitivity to diarylquinolines. M. bo-
vis BCG in late exponential phase was pelleted by centrifugation and lysed by
passages through a French press, the membrane fraction was collected by cen-
trifugation. Typically 50−100 mg membrane proteins were obtained from ∼ 3 g
cells at a concentration of 10− 20 mg mL−1. Proteins were solubilised from the
membranes with an extraction efficiency of ∼ 85% after treatment with 1.2%
DDM (1 h, 4 ◦C). As shown in table 6.1, the extracted proteins displayed ATP
hydrolysis activity, which was to ∼ 5% sensitive to DCCD. The proteins were
applied to a Resource Q anion-exchange column, eluted with a sodium chloride
gradient, and subsequently subjected to a Superdex 200 size-exclusion column.
The protein fraction with an estimated molecular mass of ∼ 550 kDa, consistent
with the mass reported for the ATP synthase holoenzyme [Boyer, 1997], was
further analysed. This fraction contained about 100µg protein and showed low,
but detectable ATP hydrolysis activity (2.94 nmol min−1 mg−1). The enhanced
DCCD-sensitivity (∼ 83%) (Table 6.1) indicates that ATP hydrolysis is indeed
caused by ATP synthase activity and that the complex is functionally coupled.
To confirm presence of ATP synthase, fractions eluted from size exclusion
chromatography were analysed by gel electrophoresis. The fraction with molec-
ular mass of 550 kDa showed a double band of proteins with a molecular mass of
50−60 kDa, typical for the main ATP synthase subunits α and β (Fig. 6.1, lane
3). The bands were excised from the gel and analyzed by mass spectrometry
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Table 6.1: Isolation of ATP synthase from M. bovis BCG.
Step Protein Specific activity DCCD-sensitive activity
(mg) (nmol min−1 mg−1) (nmol min−1 mg−1)
DDM (1.2%) 4.87 13.19 0.64 (5%)
extraction
ResourceQ 0.58 3.66 2.41 (66%)
Superdex 200 0.14 2.94 2.45 (83%)
ATP hydrolysis activities were measured at 37 ◦C by, inorganic phosphate release as described
by [Haagsma et al., 2010].
Table 6.2: Activation of ATP hydrolysis in membrane vesicles from Mycobacterium bovis
BCG and Mycobacterium smegmatis.
Gene Description Total ion score Total ion Mr
confindence interval
(%) (kDa)a
Band 1 Band 2 Band 1 Band 2
atpA ATP synthase 159 25 100 98.6 59.48
alpha chain
atpD ATP synthase 10 - 74.4 - 53.18
beta chain
atpH ATP synthase 9 20 67.3 96.2 48.83
delta chain
a Molecular weight in kDa of the respective protein.
for identification. We detected subunits α, β, and δ of the mycobacterial ATP
synthase complex (Table 6.2), suggesting that this fraction contains ATP syn-
thase. Whereas subunit α and β typically have a molecular mass of 50−60 kDa,
subunit δ in most organisms is considerably smaller 20− 25 kDa [Boyer, 1997].
However, information from the M. tuberculosis genome predicts a substantially
larger subunit δ, with a molecular mass of 49 kDa (UniProtKB accession no.
A1KI95). Apparently, in M. tuberculosis and related mycobacteria subunit δ
constitutes a fusion protein of the subunit δ as found in other bacteria and the
subunit b (UniProtKB accession no. A1KI95). Our result is thus consistent
with M. bovis BCG ATP synthase displaying an unsual subunit composition.
Previously, subunit δ was identified in proteome studies of mycobacterial mem-
branes [Xiong et al., 2005,Ma˚len et al., 2008, Zheng et al., 2007, Zheng et al.,
2011], however, these authors did not comment on the unusual size of the sub-
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Figure 6.1: SDS-PAGE separation ofMycobacterium bovis BCG membrane protein fractions
after size exclusion chromatography. Lane 1: Precision Plus ProteinTM Standard, lane 2-7;
fractions after size-exclusion chromatography (Superdex 200), lane 9: purified ATP synthase
from Bacillus PS3.
unit.
In conclusion, we have detergent-solubilised and isolated the ATP synthase
from the slow growing mycobacterium M. bovis BCG. The isolated enzyme
displays low, byt detectable ATP hydrolysis activity and is susceptible to DCCD,
indicating protein functionality. In contrast to the situation in mycobacterial
membranes, where ATP hydrolysis activity is not detectable [Haagsma et al.,
2010], for the solubilized, enriched enzyme the specific activity is sufficiently
high. Moreover, ATP synthase in detergent solubilized state may be less prone
to inactivation by by inhibitory ADP.
Our results are in line with genomic information, predicting a non-standard
subunit composition of this enzyme. The availability of isolated mycobacterial
ATP synthase may help in characterizing its function as target of the new drug
class diarylquinolines. Moreover, further characterization of mycobacterial ATP
synthase may reveal if unusual properties of this enzyme reflect adaptations
to the environment in which the bacteria reside during infection, such as low
nutrient availability or low pH conditions.
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Tuberculosis causes approximately 2 million deaths per year and an esti-
mated one third of the world population is thought to be infected with a dormant
or latent form of Mycobacterium tuberculosis [Dye & Williams, 2010,Russel et
al., 2010]. Infections with multidrug-resistant and extensively drug-resistant
mycobacterial strains as well as co-infection with HIV pose a global health chal-
lenge [Gandhi et al., 2010,Mandavilli, 2007,World Health Organization, 2010].
At present, treatment of TB involves administration of a cocktail of first-line an-
tibiotics for at least six months: isoniazid, rifampin, pyrazinamide, and etham-
butol are administered for the first two months, followed by an additional four
months of treatment with isoniazid and rifampin [Mitchison, 2005]. In case of
mutlti-drug resistant tuberculosis, the antibacterial chemotherapy is extended
to 12-24 months. This long treatment duration and concomitant low treatment
compliance contributes directly to the emergence of multidrug- and extensively
drug-resistant strains of M. tuberculosis, thus further limiting the efficacy of
standard therapy [Check, 2007,Dye, 2009]. To improve current TB treatment
new antituberculosis drugs should meet a number of criteria. The candidate
drug should be suitable for: 1. shortening treatment duration; 2. treatment of
multidrug-resistant and extensively drug-resistant TB; 3. reducing pill burden;
4. lower dosing frequency; and 5. co-administered with HIV medications [Koul
et al., 2011].
Energy metabolism has emerged as a new target for development of new an-
timycobacterial drugs [Bald & Koul, 2010,Zhang et al., 2003]. The diarylquino-
line TMC207 is highly active on drug-sensitive and multidrug-resistant repli-
cating as well as on dormant mycobacteria [Andries et al., 2005, Koul et al.,
2008,Lounis et al., 2006,Rao et al., 2008]. Moreover, TMC207 is a highly promis-
ing candidate for shortening the duration of tuberculosis treatment [Ibrahim et
al., 2007, Lounis et al., 2006]. In phase II clinical trials addition of TMC207
to standard therapy antituberculosis regimen strongly accelerated conversion to
a negative sputum as compared to placebo [Diacon et al., 2009] according to
the semi-automated mycobacteria growth indicator tube (MGIT) system. By
specifically interacting with subunit c of ATP synthase, TMC207 blocks ATP
synthesis in mycobacteria [Koul et al., 2007]. ATP synthase is evolutionarily
strongly conserved among prokaryotes and eukaryotes and in humans ATP syn-
thase is essential for survival, as it supplies cells with the bulk of their ATP via
oxidative phosphorylation [von Ballmoos et al., 2008]. For the development of
new anti-bacterial drugs, usually bacterial targets without homologue in human
metabolism are regarded as the most promising candidates. Typical inhibitors
of ATP synthase, such as dicyclohexyl-carbodiimide, oligomycin and venturi-
cidin, which block ATP synthase action by interaction with subunit c, are not
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selective and inhibit ATP synthase not only in bacteria but also in mitochon-
dria [Amacher, 2005, Matsuno-Yagi & Hatefi, 1993a, Matsuno-Yagi & Hatefi,
1993b,Wallace & Starkov, 2000]. This lack of selectivity and resulting toxicity
prevents their clinical usage. Short-term administration of TMC207 was found
to be safe and well tolerated without serious side effects in a phase I clinical
study with healthy volunteers [Andries et al., 2005]. Also, in the first stages of
phase 2 clinical trials, administration of TMC207 to patients with multi-drug
resistant tuberculosis gave an acceptable side-effect profile over a longer period
of time [Diacon et al., 2009]. Results from this thesis demonstrate a 20, 000-fold
lower TMC207 sensitivity for human mitochondrial ATP synthase as compared
to mycobacterial ATP synthase (Chapter 2). This high selectivity index for
TMC207 indicates that the compound is highly specific and unlikely to induce
target-based toxicity in mammalian cells. Our results thus provide a ratio-
nale for the clinical safety observed for this compound. The data presented in
Chapter 2 suggest that TMC207 may be the first highly selective ATP synthase
inhibitor with the potential to treat a bacterial infection. Furthermore, ATP
synthase, although highly conserved between prokaryotes and eukaryotes, may
still qualify as an attractive antibiotic target.
Transposon mutagensis analysis suggested that ATP synthase is an essen-
tial enzyme for growth in M. tuberculosis [Sassetti et al., 2003] and for growth
on fermentable and nonfermentable carbon sources in M. smegmatis [Tran &
Cook, 2005]. However, it is not known whether the observed essentiality stems
from a need for ATP synthase to synthesize ATP or to maintain the proton
motive force by hydrolysis of ATP. A number of known inhibitors of ATP syn-
thase, such as sodium azide and aurovertin, strongly discriminate between the
enzyme in ATP synthesis mode or in the ATP hydrolysis mode [Syroeshkin et
al., 1995, Bald et al., 1998, Johnson et al., 2009]. To understand diarylquino-
line action and selectivity, insight in the mode of action of mycobacterial ATP
synthase is important. ATP synthase from fast-growing saprophytic strains
(generation time < 3 h) does not seem able to efficiently invert its function to
pump protons across the membrane, as only a very low ATP hydrolysis activity
is displayed by Mycobacterium phlei [Higashi et al., 1975] and TMC207 had no
significant effect on the proton motive force in M. smegmatis [Koul et al., 2008].
The most relevant pathogenic strains, like M. tuberculosis, Mycobacterium lep-
rae, Mycobacterium ulcerans as well as the vaccine strain Mycobacterium bovis
Bacillus Calmette-Guerin (BCG) are slow-growers with a generation time > 15
h and with significantly different energy requirements [Beste et al., 2009,Cook
et al., 2009]. In Chapter 3 we used M. bovis BCG, which shares > 99.9% DNA
sequence identity with M. tuberculosis and strongly resembles M. tuberculosis
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in terms of sensitivity to diarylquinolines [Mattow et al., 2001, Huitric et al.,
2007], as model system for biochemical studies on mycobacterial ATP synthase.
We set up an experimental system to investigate ATP synthase and the respi-
ratory chain in coupled inverted membrane vesicles from this model strain. We
show that inverted membrane vesicles from M. bovis BCG are active in ATP
synthesis, but ATP synthase displays no significant ATP hydrolysis activity and
does not set-up a proton motive force using ATP as a substrate. Treatment with
methanol as well as PMF activation unmasked the ATP hydrolysis activity, in-
dicating that the intrinsic subunit ε and inhibitory ADP are responsible for the
suppression of hydrolytic activity. The results in Chapter 3 indicate that ATP
synthase is needed for the synthesis of ATP, but not for the maintenance of the
proton motive force in mycobacteria. Thus, it seems that for the development
of new antimycobacterial drugs acting on ATP synthase, screening for ATP
synthesis inhibitors, but not for ATP hydrolysis blockers, can be regarded as a
promising strategy.
Docking studies predict a binding niche for TMC207 in ATP synthase, which
is mainly made up by subunit c, supplemented with residues from subunit a [de
Jonge et al., 2007,Upadhayaya et al., 2009]. Point mutations influencing my-
cobacterial sensitivity to TMC207 are located in the vicinity of the essential
acidic residue Glu61 in the central membrane-spanning region of subunit c [An-
dries et al., 2005,Petrella et al., 2006,Huitric et al., 2010]. TMC207 has been
proposed to interact via its protonated basic amino group with Glu61 in subunit
c [de Jonge et al., 2007,Upadhayaya et al., 2009]. In Chapter 4 no competition
between TMC207 and protons for a common binding site is observed, suggest-
ing that protonated TMC207 may block conformational changes associated with
proton flow and thereby interfere with proton transfer. TMC207 binding can be
described with a one-site binding mode with electrostatic interactions mediating
drug target interaction. Our results are consistent with and provide experimen-
tal support for the binding model based on docking studies, where TMC207 pre-
vents rotation of subunit c by mimicking the function of arginine186 in subunit
a [de Jonge et al., 2007]. Furthermore, independent of environmental conditions
such as the local pH and the proton motive force, TMC207 can efficiently bind
to its target. These properties, combined with the essentiality of the target,
may explain how TMC207 can act as a highly potent antibacterial drug.
TMC207 diplays a delayed bactericidal effect, with the onset of bacterial
killing 3-4 days after drug addition [Lounis et al., 2006]. This delayed killing dis-
tinguishes TMC207 from most other antibacterials. In this work, the metabolic
response to TMC207 was investigated with a proteomics approach using M. bo-
vis BCG as model strain (Chapter 5). The observed downregulation of biosyn-
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thetic pathways, in particular of the protein synthesis machinery reveals how
the bacteria remodel their metabolism, thus saving energy, and may in part
explain why the mycobacteria can survive for several days in presence of the
drug.
Mycobacterial ATP synthase has been solubilized and purified in the past
[Higashi et al., 1975], but these studies used a fast growing model strain,
M. phlei. Biochemical data on ATP synthase from slow-growing strains, the
causative agents of diseases such as tuberculosis and leprosy, are scarce. In
this thesis, we detergent-solubilized and isolated ATP synthase from the slow-
growing strain M. bovis BCG. Our results indicate an unsual subunit composi-
tion of this enzyme, consistent with predictions from genomic data.
Outlook
In vivo experiments using mouse models indicated that diarylquinolines have
bactericidal activity exceeding the effect of current first-line antibiotics [An-
dries et al., 2005,Lounis et al., 2006]. Diarylquinolines, in particular when ap-
plied in combination therapy with the first-line antibiotic pyrazinamide, have a
strong potential for shortening the duration of tuberculosis treatment [Ibrahim
et al., 2007, Lounis et al., 2006]. The sub-cellular membrane assay described
in Chapter 3 together with the proteomics approach used in Chapter 5 may
help to elucidate the physiological basis for this observed synergy. Moreover,
this assay system using membranes from slow-growing mycobacteria may be
used in multiple-target screening for identification and characterization of new
respiratory pathway inhibitors.
Based on the structure of diarylquinolines, novel quinoline derivatives with
significant in vitro bactericidal activity on M. tuberculosis have been synthe-
sized [Lilienkampf et al., 2009,Upadhayaya et al., 2009]. The biochemical assays
and binding studies to investigate the mode of binding between TMC207 and
mycobacterial ATP synthase presented in Chapter 4 may here provide input for
design of new compound derivatives. The ability to act independent of physio-
logical conditions, e.g. pH and proton motive force, as found for TMC207 consti-
tutes a very important property for an anti-tuberculosis drug, as mycobacteria
during infections are found in a variety of physiological micro-environmnents.
Elucidating the metabolic response of mycobacteria to TMC207, described
in Chapter 5, revealed a number of enzymes and patwhays that are differentially
up- or downregulated. Drugs acting on these pathways may act synergistically
with TMC207 and thus be promising for combination regimens.
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Availability of ATP synthase from slow growing mycobacteria in detergent-
solubilized, isolated form, as reported in Chapter 6, may help elucidating special
adaptations of this enzyme, such as the properties and function of the unusual
stator subunit δ or the regulating subunit ε. The purified enzyme may also be
used for drug target interaction studies, e.g. to understand the high affinity and
selectivity of diarylquinoline binding to ATP synthase. Conversely, TMC207 as
an inhibitor may be used as a new probe to investigate the mechanism of ATP
synthase.
Diarylquinolines, with lead compound TMC207, are expected to be intro-
duced in the regimen for treatment of multi-drug resistant tuberculosis within
the next 1-3 years. Characterizing and understanding diarylquinoline mecha-
nism of action may help to find more drug classes with new mechanism acting
on new targets, which is urgently needed to combat drug resistant infectious
diseases.
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Samenvatting
ATP synthase is een membraaneiwit dat een essentie¨le rol speelt in het en-
ergiemetabolisme van de levende cel. Vanuit evolutionair standpunt gezien is
ATP synthase sterk geconserveerd tussen eukaryoten en prokaryoten. In de
meeste organismen is de primaire functie van het enzym het synthetiseren van
adenosine trifosfaat (ATP), van adenosine difosfaat (ADP) en van inorganisch
fosfaat. ATP synthase is een essentieel enzym in het energiemetabolisme van
de pathogene bacterie Mycobacterium tuberculosis. Deze bacterie groeit heel
langzaam en kan jaren zonder celdeling in het menselijk lichaam overleven. Het
energie metabolisme van de tuberkelbacterie, en ATP synthase in het bijzonder,
is mogelijk aangepast aan deze omgeving en kan verschillen tonen vergeleken
met andere bacterin en ook met het energie metabolisme in menselijke cellen.
Wij hebben onderzoek gedaan naar ATP synthase in dit pathogeen en hebben
kunnen aantonen dat ATP synthase in mycobacterie¨n efficie¨nt ATP kan produc-
eren, maar in tegenstelling tot andere enzymen, deze functie niet kan omdraaien.
Dit is mogelijk een adaptatiemechanisme om voor de bacterie om te overleven
in een omgeving met lage hoeveelheden voedingsstoffen.
De Wereldgezondheidsorganisatie (WHO) heeft tuberculose (TB) uitgeroep-
en tot een wereldwijd gezondheidsprobleem. Ee´n derde van de werelbevolking
is besmet met TB en elk jaar overlijden er ongeveer 2 miljoen mensen aan.
Veel tuberculose bacterie¨n zijn ongevoelig voor de tegenwoordig gebruikte an-
tibiotica en de ontwikkeling van nieuwe drugs is dus belangrijk. Recentelijk
werd aangetoond dat ATP synthase als aangrijppunt van nieuwe geneesmidde-
len tegen tuberculose kan werken. De diarylquinolines, een nieuwe familie van
geneesmiddelen, binden specifiek aan ATP synthase van M. tuberculosis. Typ-
ische remmers van ATP synthase zijn niet selectief en remmen ATP synthase
niet alleen in bacterie¨n maar ook in menselijke mitochondrie¨n. De toediening
van de diarylquinoline TMC207 aan gezonde personen gedurende een korte pe-
riode wordt goed getolereerd en geeft geen ernstige bijwerkingen in een fase I
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klinische studie. We hebben kunnen aantonen dat mycobacterieel ATP synthase
meer dan 20.000 keer gevoeliger is dan menselijke ATP synthase voor TMC207.
Het is daardoor onwaarschijnlijk dat TMC207 toxisch zal zijn voor cellen van
zoogdieren. Wij hebben ook het bindingsmechanisme van TCM207 en ATP
synthase onderzocht, de resultaten geven support aan een mechanisme dat door
computer analyses voorspeld werd. De drug bindt onafhankelijk van omgev-
ingsfactoren zoals de pH waarde of de hoeveelheid beschikbare energie, een be-
langrijke eigenschap voor tuberculose drugs. Een proteom analyse verhelderde
het metabolische respons van de bacterie¨n op toediening van het antibioticum,
deze resultaten kunnen helpen bij het vinden van “zwakke punten” van de tu-
berkelbacterie. De beschikbaarheid van ge¨ısoleerd mycobacterieel ATP synthase
zou van nut kunnen zijn om de binding tussen TMC207 en ATP synthase te
onderzoeken. Daarnaast zou het ge¨ısoleerde ATP synthase informatie kunnen
verschaffen over de ongewoonlijke subunit compositie van het eiwit.
De experimenten en resultaten van dit proefschrift kunnen een belangrijke
bijdrage leveren aan zowel fundamenteel begrip van energie metabolisme en
ATP synthese in pathogene bacterie¨n als ook aan de ontwikkeling van nieuwe
geneesmiddelen die energieomzet in tuberkelbacterie¨ remmen.
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